WO2022166987A1 - Anticorps se liant à lag-3 et leur utilisation - Google Patents

Anticorps se liant à lag-3 et leur utilisation Download PDF

Info

Publication number
WO2022166987A1
WO2022166987A1 PCT/CN2022/075525 CN2022075525W WO2022166987A1 WO 2022166987 A1 WO2022166987 A1 WO 2022166987A1 CN 2022075525 W CN2022075525 W CN 2022075525W WO 2022166987 A1 WO2022166987 A1 WO 2022166987A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
variable region
amino acid
chain variable
heavy chain
Prior art date
Application number
PCT/CN2022/075525
Other languages
English (en)
Chinese (zh)
Inventor
王荣娟
焦莎莎
张畅
王双
Original Assignee
迈威(上海)生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 迈威(上海)生物科技股份有限公司 filed Critical 迈威(上海)生物科技股份有限公司
Publication of WO2022166987A1 publication Critical patent/WO2022166987A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Definitions

  • the present invention relates to the field of antibody drugs.
  • the present invention relates to novel antibodies and antibody fragments that specifically bind to LAG-3 and compositions containing the antibodies or antibody fragments.
  • the present invention relates to nucleic acids encoding said antibodies and host cells comprising said nucleic acids, and methods of making said antibodies.
  • the present invention also relates to the therapeutic and diagnostic uses of these LAG-3 binding antibodies.
  • Immune cells are regulated by a variety of inhibitory immune checkpoint molecules that act as "security brakes" at various stages of the immune response. These regulations are important in preventing tissue damage due to inappropriate immune responses to invading pathogens. Cancer cells, however, use these inhibitory immune checkpoint molecules to evade the immune response of immune cells that specifically destroy tumors.
  • cytotoxic T lymphocyte-associated protein 4 CTLA-4, CD152
  • programmed death 1 PD-1, CD279
  • its ligand PD-L1 CD274, B7-H1
  • mAbs monoclonal antibodies
  • TILs tumor-infiltrating lymphocytes
  • suppressive myeloid cells the frequency of patient responses to the use of monoclonal antibodies against these immune checkpoint molecules is suboptimal (Awad, R.M.
  • LAG-3 also known as CD223, is a member of the immunoglobulin superfamily and consists of three parts: the extracellular domain, the transmembrane domain and the cytoplasmic domain.
  • the gene of LAG-3 is located on chromosome 12 (12P13), which is similar to CD4 in chromosomal location and structure, but the amino acid sequence of the two is only 20% homologous.
  • LAG-3 is mainly expressed on the surface of T cells (especially activated T cells), natural killer cells, B cells and plasmacytoid dendritic cells. It has been shown that LAG-3 is an inhibitory receptor with functions of maintaining homeostasis and participating in immune regulation, and is closely related to the occurrence and development of tumors.
  • the major ligand of LAG-3 is histocompatibility complex class II (MHC-II), in addition, galectin-3 (Galectin-3), hepatic sinusoidal endothelial cell lectin (LSECtin) and fibrinogen-like protein 1 (FGL-1) is also its ligand. In the tumor microenvironment, LSECtin, galectin-3 and FGL-1 can interact with LAG-3 to inhibit the antitumor activity of CD8+ T cells.
  • MHC-II histocompatibility complex class II
  • Galectin-3 galectin-3
  • LSECtin hepatic sinusoidal endothelial cell lectin
  • LAG-3-expressing regulatory T cells In cancer, LAG-3-expressing regulatory T cells (Treg) have enhanced suppressive antitumor activity, whereas LAG-3-expressing cytotoxic CD8+ T cells have reduced proliferation rate and effector cytokine production (Scurr M. et al., Highly prevalent colorectal cancer-infiltrating LAP + Foxp3 - T cells exhibit more potent immunosuppressive activity than Foxp3 + regulatory T cells, Mucosal Immunol. 2014, 7(2): 428-439).
  • LAG-3 is expressed at elevated levels in many tumor-infiltrating Treg cells, which are also expressed in peripheral blood and tumor tissues of patients with melanoma and colorectal cancer, and MHC-II expressed on antigen-presenting cells (APCs) is associated with The interaction between LAG-3 on Treg cells can produce immunosuppressive cytokines, thereby inhibiting the activity of CD8+ TILs.
  • the antibodies or antigen-binding fragments of the invention that specifically bind to LAG-3 have one or more of the following properties:
  • Binds LAG-3 with high affinity eg, human LAG-3 and cynomolgus LAG-3, eg, the anti-LAG-3 antibody or antigen-binding fragment thereof has a K for binding to LAG-3 of about 10 -7 M to about 10-12 M, preferably, about 10-8 M to about 10-12 M, as measured by the ForteBio kinetic binding assay;
  • LAG-3 specifically blocking the binding of LAG-3 to cell surface MHC class II molecules (eg, human HLA);
  • the present invention provides an isolated antibody or antigen-binding fragment that specifically binds LAG-3, comprising
  • the invention provides an isolated antibody or antigen-binding fragment that specifically binds LAG-3, comprising a heavy chain variable region and a light chain variable region, wherein
  • the heavy chain variable region comprises HCDR1 shown in SYGIS (SEQ ID NO: 31), or a variant of said HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; EIYPRSDNTYYNGKFKG (SEQ ID NO: 31) NO: 32), or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in RAFYYYGSNYYAMDY (SEQ ID NO: 33), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises LCDR1 shown in RSSQSIVHSNGDTYLE (SEQ ID NO: 34), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in KVSNRFS (SEQ ID NO: 35), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change;
  • the heavy chain variable region comprises HCDR1 shown in NYAMS (SEQ ID NO: 37), or a variant of said HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; TITYGTTYTFYSDNVKG (SEQ ID NO: 37) NO: 38), or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in GEYGSSFAY (SEQ ID NO: 39), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change;
  • the light chain variable region comprises LCDR1 as shown in KASQNVRTAVA (SEQ ID NO: 40), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in LASNRHT (SEQ ID NO: 41), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and LQHWNYPLT (S
  • variable region of the heavy chain comprises HCDR1 shown in DYAVS (SEQ ID NO: 43), or a variant of the HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; VVWGDGSTNYHSALIS (SEQ ID NO: 43) NO: 44) shown in HCDR2, or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in GGGGMDY (SEQ ID NO: 45), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises LCDR1 shown in RASSSVSYMH (SEQ ID NO: 46), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in ATSNLAS (SEQ ID NO: 47), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and QHYNTNPPT
  • variable region of the heavy chain comprises HCDR1 shown in DDYMH (SEQ ID NO: 49), or a variant of the HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; RIDPEDVETKYDPKFQG (SEQ ID NO: 49) NO:50), or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO:51), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises LCDR1 shown in KASENVGTYVS (SEQ ID NO: 52), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in GASNRYT (SEQ ID NO: 53), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and GQ
  • the heavy chain variable region comprises HCDR1 set forth in DDYMH (SEQ ID NO: 49); HCDR2 set forth in RIX 1 PEDVETKYDPKFQG (SEQ ID NO: 64), preferably, wherein X 1 is D or N; and HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51);
  • the light chain variable region comprises LCDR1 shown by X 2 ASENVGTYVS (SEQ ID NO: 68), preferably, wherein X 2 is K or R; LCDR2 shown by X 3 ASX 4 RYT (SEQ ID NO: 69) , preferably; wherein X 3 is G or A; X 4 is N or T; and LCDR3 shown in GQSYSYPYT (SEQ ID NO: 54);
  • the heavy chain variable region comprises HCDR1 shown in DDYMH (SEQ ID NO:49); HCDR2 shown in RIDPEDVETKYDPKFQG (SEQ ID NO:50); and HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO:51);
  • the light chain variable region comprises LCDR1 shown in KASENVGTYVS (SEQ ID NO: 52), LCDR2 shown in GASNRYT (SEQ ID NO: 53), and LCDR3 shown in GQSYSYPYT (SEQ ID NO: 54);
  • the heavy chain variable region comprises HCDR1 shown in DDYMH (SEQ ID NO: 49); HCDR2 shown in RIDPEDVETKYDPKFQG (SEQ ID NO: 50), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51);
  • the chain variable region comprises LCDR1 shown in KASENVGTYVS (SEQ ID NO: 52), LCDR2 shown in AASNRYT (SEQ ID NO: 66), and LCDR3 shown in GQSYSYPYT (SEQ ID NO: 54);
  • the heavy chain variable region comprises HCDR1 shown in DDYMH (SEQ ID NO: 49); HCDR2 shown in RIDPEDVETKYDPKFQG (SEQ ID NO: 50), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51);
  • the chain variable region comprises LCDR1 represented by RASENVGTYVS (SEQ ID NO:65), LCDR2 represented by GASNRYT (SEQ ID NO:53), and LCDR3 represented by GQSYSYPYT (SEQ ID NO:54);
  • the heavy chain variable region comprises HCDR1 shown in DDYMH (SEQ ID NO: 49); HCDR2 shown in RIDPEDVETKYDPKFQG (SEQ ID NO: 50), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51);
  • the chain variable region comprises LCDR1 shown by KASENVGTYVS (SEQ ID NO:52), LCDR2 shown by GASTRYT (SEQ ID NO:67), and LCDR3 shown by GQSYSYPYT (SEQ ID NO:54); the heavy chain can be
  • the variable region comprises HCDR1 represented by DDYMH (SEQ ID NO: 49); HCDR2 represented by RINPEDVETKYDPKFQG (SEQ ID NO: 63), HCDR3 represented by SFYSNYVNYFDQ (SEQ ID NO: 51);
  • the light chain variable region comprises LCDR1 shown by KASENVGTYVS (SEQ ID NO:52), LCDR2 shown by GASNRYT (SEQ ID
  • the heavy chain variable region comprises HCDR1 shown in DDYMH (SEQ ID NO: 49); HCDR2 shown in RINPEDVETKYDPKFQG (SEQ ID NO: 63), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51);
  • the chain variable region comprises LCDR1 represented by KASENVGTYVS (SEQ ID NO:52), LCDR2 represented by AASNRYT (SEQ ID NO:66), and LCDR3 represented by GQSYSYPYT (SEQ ID NO:54); or
  • the heavy chain variable region comprises HCDR1 shown in DDYMH (SEQ ID NO: 49); HCDR2 shown in RINPEDVETKYDPKFQG (SEQ ID NO: 63), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51);
  • the chain variable region comprises LCDR1 shown by KASENVGTYVS (SEQ ID NO:52), LCDR2 shown by GASTRYT (SEQ ID NO:67), and LCDR3 shown by GQSYSYPYT (SEQ ID NO:54);
  • the heavy chain variable region comprises HCDR1 shown in DDYMH (SEQ ID NO: 49), or a variant of said HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; WIDPENGETEYASKFQG (SEQ ID NO: 49) NO: 55) shown in HCDR2, or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in FDY (SEQ ID NO: 56), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises LCDR1 as shown in KSSQSLLDSDGKTYLN (SEQ ID NO: 57), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in LVSKLDF (SEQ ID NO: 58), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change;
  • the heavy chain variable region comprises HCDR1 shown in NYGIS (SEQ ID NO: 60), or a variant of said HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; EIYPRGGNTYYNGKFKG (SEQ ID NO: 60) NO: 61), or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in RAFYYFGSNYYAMDY (SEQ ID NO: 62), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises LCDR1 shown in RSSQSIVHSNGDTYLE (SEQ ID NO: 34), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in KVSNRFS (SEQ ID NO: 35), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change
  • the invention provides an isolated antibody or antigen-binding fragment that specifically binds LAG-3, comprising a heavy chain variable region and a light chain variable region, wherein
  • the heavy chain variable region comprises or is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 1 and the light chain variable region comprises or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the sequence of SEQ ID NO: 2 % sequence of identity;
  • the heavy chain variable region comprises or is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:3 and the light chain variable region comprises or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the sequence of SEQ ID NO:4 % sequence of identity;
  • the heavy chain variable region comprises or is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:5 and the light chain variable region comprises or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the sequence of SEQ ID NO:6 % sequence of identity;
  • the heavy chain variable region comprises or is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:7 and the light chain variable region comprises or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the sequence of SEQ ID NO: 8 % sequence of identity;
  • the heavy chain variable region comprises the sequence of SEQ ID NO: 15 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto , and the light chain variable region comprises or is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 16 sequence; or
  • the heavy chain variable region comprises the sequence of SEQ ID NO: 15 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto , and the light chain variable region comprises or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the sequence of SEQ ID NO: 17 the sequence of;
  • the heavy chain variable region comprises or is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO:9 and the light chain variable region comprises or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the sequence of SEQ ID NO: 10 % sequence of identity;
  • the heavy chain variable region comprises or is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 11 and the light chain variable region comprises or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the sequence of SEQ ID NO: 12 % sequence of identity.
  • the isolated antibody or antigen-binding fragment of the invention is a humanized antibody.
  • the isolated antibody or antigen-binding fragment of the invention is an IgGl, IgG2, IgG3 or IgG4 antibody; preferably, an IgGl or IgG4 antibody; more preferably, a humanized IgGl or humanized IgG4 antibody .
  • the antigen-binding fragment of the invention is a Fab, Fab', F(ab') 2 , Fv, single-chain Fv, single-chain Fab, or diabody.
  • the present invention provides a nucleic acid encoding the antibody or antigen-binding fragment of the first aspect above, a vector (preferably, an expression vector) comprising the nucleic acid, and a host cell comprising the nucleic acid or the vector .
  • the host cell is prokaryotic or eukaryotic, eg, selected from E. coli cells, yeast cells, mammalian cells, or other cells suitable for the production of antibodies or antigen-binding fragments, multispecific antibodies.
  • the host cell is a 293 cell or a CHO cell.
  • the invention provides a method of making an antibody or antigen-binding fragment of the invention, the method comprising culturing a host cell of the invention under conditions suitable for expression of the antibody or antigen-binding fragment encoding the invention, optionally The antibody or antigen-binding fragment of the invention is recovered from the host cell or from the culture medium.
  • the present invention provides a pharmaceutical composition comprising an antibody or antigen-binding fragment of the present invention and a pharmaceutically acceptable carrier.
  • the present invention provides pharmaceutical compositions comprising an antibody of the present invention and other therapeutic agents, and optionally a pharmaceutically acceptable carrier; preferably, the other therapeutic agents are selected from chemotherapeutic agents, other antibodies ( For example, anti-PD-1 antibody or anti-PD-L1 antibody), cytotoxic agent.
  • the other therapeutic agents are selected from chemotherapeutic agents, other antibodies ( For example, anti-PD-1 antibody or anti-PD-L1 antibody), cytotoxic agent.
  • the present invention provides a combination product comprising an antibody of the present invention, and one or more other therapeutic agents, such as chemotherapeutic agents, cytotoxic agents, other antibodies, preferably anti-PD-1 antibodies or anti-PD-1 antibodies PD-L1 antibody.
  • therapeutic agents such as chemotherapeutic agents, cytotoxic agents, other antibodies, preferably anti-PD-1 antibodies or anti-PD-1 antibodies PD-L1 antibody.
  • the present invention provides a method of preventing or treating a tumor or infectious disease in a subject or individual, comprising administering to the subject an effective amount of an antibody, pharmaceutical composition, or combination of the present invention product.
  • the tumor prevented or treated by the antibody, pharmaceutical composition, or combination product of the invention is a cancer, such as a cancer with elevated expression levels of LAG-3; or the antibody, pharmaceutical composition, or combination product of the invention.
  • the infectious disease that is prevented or treated by the combination product is, for example, a bacterial infection, a viral infection, a fungal infection or a protozoal infection, preferably the infectious disease is a chronic infection in which elevated LAG-3 expression levels lead to The subject or individual is immunocompromised.
  • the present invention provides a kit for detecting LAG-3 in a sample, the kit comprising the antibody of the present invention, for implementing the following steps:
  • Figure 1 shows the results of detecting the specific binding activity of the anti-human LAG-3 chimeric antibody to LAG-3 on the surface of 293/rhLAG-3 cells by the FACS method.
  • the negative control in the figure is the isotype control antibody, which is a purified monoclonal antibody of the human IgG4 isotype that does not bind to the LAG-3 molecule, and MFI represents the mean fluorescence intensity.
  • Figure 2 shows the results of blocking the binding of 293/rhHLA cells to hLAG-3 by anti-human LAG-3 chimeric antibody detected by FACS method.
  • Figure 3 shows the results of detecting the binding of anti-human LAG-3 humanized antibody to recombinant human LAG-3 by ELISA.
  • Figure 4 shows the results of detecting the binding of anti-human LAG-3 humanized antibody to recombinant cynomolgus monkey LAG-3 by ELISA.
  • Figure 5 shows the results of detecting the binding of anti-human LAG-3 humanized antibody to recombinant mouse LAG-3 by ELISA.
  • Figure 6 Graph showing the results of the affinity of the anti-human LAG-3 humanized antibodies of the present invention for human LAG-3 extracellular domain recombinant protein measured by ForteBio kinetic binding assay.
  • FIG. 7 Graph showing the results of the affinity of BMS-986016 for human LAG-3 extracellular domain recombinant protein measured by ForteBio kinetic binding assay.
  • BMS-986016 is a monoclonal antibody targeting LAG-3 developed by BMS.
  • Figure 8 shows the results of detecting the specific binding of the anti-human LAG-3 humanized antibody of the present invention to LAG-3 on the surface of 293/rhLAG-3 cells by FACS method.
  • FIG. 9 shows the result of blocking the binding of human FGL-1 to LAG-3 by the anti-human LAG-3 humanized antibody of the present invention by ELISA.
  • Figure 10 shows the results of blocking the binding of 293/rhHLA cells to hLAG-3 by anti-human LAG-3 humanized antibody detected by FACS.
  • Figure 11 shows the inhibitory effect of the anti-human LAG-3 humanized antibody of the present invention on tumor growth in a B6-huLAG3 humanized mouse subcutaneous tumor model.
  • Figure 12 shows the effect of the anti-human LAG-3 humanized antibody of the present invention on the body weight of mice in the B6-huLAG3 humanized mouse subcutaneous tumor model.
  • antibody is used herein in the broadest sense to refer to a protein comprising an antigen-binding site, and encompasses natural and artificial antibodies of various structures, including but not limited to monoclonal, polyclonal, multispecific (for example, bispecific antibodies), single chain antibodies, whole antibodies and antibody fragments.
  • the antibody of the present invention is a single domain antibody or a heavy chain antibody.
  • Antibody fragment or "antigen-binding fragment” are used interchangeably herein to refer to a molecule other than an intact antibody that comprises a portion of the intact antibody and binds the antigen to which the intact antibody binds.
  • antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv, single chain Fv, single chain Fab, or diabodies.
  • an antibody that exhibits the same or similar binding affinity and/or specificity as a reference antibody refers to an antibody capable of binding at least 50%, 60%, 70%, 80%, 90% or 95% or more of the reference antibody Affinity and/or specificity. This can be determined by any method known in the art for determining binding affinity and/or specificity.
  • the reference antibody is a monoclonal antibody targeting LAG-3 developed by BMS Corporation: BMS-986016.
  • CDR regions are loops in the variable domains of antibodies that are hypervariable in sequence and form structurally defined loops ("hypervariable loops") and/or contain antigen-contacting residues ( "antigen contact point”).
  • the CDRs are mainly responsible for binding to antigenic epitopes.
  • the CDRs of the heavy chain are commonly referred to as CDR1, CDR2 and CDR3, numbered sequentially from the N-terminus.
  • each CDR can be determined using any one or a combination of many well-known antibody CDR assignment systems, including, for example, antibody-based three-dimensional Structure and topology of CDR loops in Chothia (Chothia et al. (1989) Nature 342:877-883, Al-Lazikani et al, "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 ( 1997)), Kabat based on antibody sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 4th edition, U.S.
  • a CDR can also be determined based on having the same Kabat numbering position as a reference CDR sequence (eg, any of the CDRs exemplified by the invention).
  • references to antibody variable regions and specific CDR sequences refer to the numbering positions according to the Kabat numbering system.
  • CDRs vary from antibody to antibody, only a limited number of amino acid positions within CDRs are directly involved in antigen binding. Using at least two of the Kabat, Chothia, AbM and Contact methods, the region of minimum overlap can be determined, thereby providing the "minimum binding unit" for antigen binding.
  • the minimal binding unit can be a sub-portion of a CDR.
  • the residues of the remainder of the CDR sequence can be determined by the structure and protein folding of the antibody, as will be apparent to those skilled in the art. Accordingly, the present invention also contemplates variants of any of the CDRs presented herein. For example, in a variant of a CDR, the amino acid residues of the smallest binding unit may remain unchanged, while the remaining CDR residues as defined by Kabat or Chothia or AbM may be replaced by conservative amino acid residues.
  • chimeric antibody is an antibody molecule in which (a) a constant region or portion thereof is altered, substituted or exchanged such that the antigen binding site is linked to a constant region of a different or altered class and/or species or confers chimeric or (b) use variable domains or portions thereof with variable domains having different or altered antigen specificities Alter, replace or exchange.
  • murine antibodies can be modified by replacing their constant regions with those from human immunoglobulins. Due to the replacement of human constant regions, the chimeric antibody can retain its specificity in recognizing the antigen while having reduced antigenicity in humans as compared to the original murine antibody.
  • a “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs.
  • all or substantially all of the CDRs (eg, CDRs) in the humanized antibody correspond to those of a non-human antibody
  • all or substantially all of the FRs correspond to those of a human antibody.
  • a humanized antibody may optionally contain at least a portion of an antibody constant region derived from a human antibody.
  • a "humanized form" of an antibody (eg, a non-human antibody) refers to an antibody that has been humanized.
  • Human antibody refers to an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human or human cell or derived from a non-human source, utilizing a library of human antibodies or other human Antibody coding sequences. This definition of human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.
  • Fc region is used herein to define the C-terminal region of an immunoglobulin heavy chain comprising at least a portion of the constant region.
  • the term includes native sequence Fc regions and variant Fc regions.
  • the human IgG heavy chain Fc region extends from Cys226 or Pro230 to the carbonyl terminus of the heavy chain.
  • the C-terminal lysine (Lys447) of the Fc region may or may not be present.
  • the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, which is also known as the EU index, as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National As described in Institutes of Health, Bethesda, MD, 1991.
  • variable region refers to the domain of an antibody heavy or light chain that is involved in antibody binding to an antigen.
  • the variable domains of the heavy and light chains of native antibodies generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three complementarity determining regions (CDRs).
  • FRs conserved framework regions
  • CDRs complementarity determining regions
  • binding means that binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions.
  • the ability of an antibody to bind to a particular antigen can be determined by enzyme-linked immunosorbent assay (ELISA), SPR or biofilm interferometry, or other conventional binding assays known in the art.
  • immune checkpoint molecule means a class of inhibitory signaling molecules present in the immune system that avoid tissue damage by regulating the persistence and strength of immune responses in peripheral tissues and are involved in maintaining tolerance to self-antigens (Pardoll DM. , The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12(4):252-264). Studies have found that one of the reasons why tumor cells can escape the immune system and proliferate out of control is the use of the inhibitory signaling pathway of immune checkpoint molecules, thereby inhibiting the activity of T lymphocytes, so that T lymphocytes cannot effectively kill tumors. Effects (Yao S, Zhu Y and Chen L., Advances in targeting cell surface signaling molecules for immune modulation. Nat Rev Drug Discov, 2013, 12(2):130-146). Immune checkpoint molecules include, but are not limited to, LAG-3, programmed death 1 (PD-1), PD-L2, CTLA-4, TIM-3.
  • PD-1 programmed death 1
  • PD-L2 CTLA-4
  • costimulatory molecule refers to a corresponding binding partner on a cell that specifically binds to a costimulatory ligand to mediate a co-stimulatory response (such as, but not limited to, proliferation) of the cell.
  • Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that contribute to an effective immune response.
  • Costimulatory molecules include, but are not limited to, MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), activating NK cell receptors, OX40 , CD40, GITR, 4-1BB (ie CD137), CD27 and CD28.
  • a "costimulatory molecule” is CD28, OX40, GITR, 4-1BB (ie, CD137) and/or CD27.
  • an “immunoconjugate” is an antibody conjugated to one or more other substances, including but not limited to cytotoxic agents or labels.
  • inhibitor refers to the reduction of some parameter (eg, activity) of a given molecule (eg, an immune checkpoint molecule).
  • a given molecule eg, an immune checkpoint molecule
  • this term includes substances that cause the activity of a given molecule (eg, LAG-3) to be inhibited by at least 5%, 10%, 20%, 30%, 40%, or more. Therefore, inhibition does not have to be 100%.
  • mammals include, but are not limited to, domesticated animals (eg, cattle, sheep, cats, dogs, and horses), primates (eg, humans and non-human primates such as monkeys), rabbits, and rodents (eg, mice and large mouse).
  • domesticated animals eg, cattle, sheep, cats, dogs, and horses
  • primates eg, humans and non-human primates such as monkeys
  • rabbits eg, mice and large mouse
  • rodents eg, mice and large mouse.
  • the individual or subject is a human.
  • tumor and cancer are used interchangeably herein to encompass both solid and liquid tumors.
  • cancer and “cancerous” refer to a physiological disorder in mammals in which cell growth is unregulated.
  • tumor refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • cancer refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • cancer refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • Tumor immune escape refers to the process by which tumors evade immune recognition and clearance. Thus, as a therapeutic concept, tumor immunity is “treated” when such escape is diminished, and the tumor is recognized and attacked by the immune system. Examples of tumor recognition include tumor binding, tumor shrinkage, and tumor clearance.
  • infectious disease refers to a disease caused by a pathogen, including, for example, a viral infection, a bacterial infection, a fungal infection, or an infection of a protozoan such as a parasite.
  • label refers to a compound or composition that is conjugated or fused, directly or indirectly, to an agent, such as an antibody, and facilitates detection of the agent to which it is conjugated or fused.
  • the label can itself be detectable (eg, a radioisotope label or a fluorescent label) or, in the case of an enzymatic label, can catalyze a detectable chemical change of a substrate compound or composition.
  • the term is intended to encompass direct labeling of a probe or antibody by coupling (ie, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of a probe or antibody by reaction with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin so that it can be detected with fluorescently labeled streptavidin.
  • an “isolated” antibody means that it has been separated from components of its natural environment.
  • the LAG-3 antibody is purified to greater than 95% or 99% purity, such as by, eg, electrophoresis (eg, SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (eg, ion exchange or reversed-phase HPLC).
  • electrophoresis eg, SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
  • chromatography eg, ion exchange or reversed-phase HPLC
  • isolated nucleic acid refers to a nucleic acid molecule that has been separated from components of its natural environment.
  • An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location different from its natural chromosomal location.
  • isolated LAG-3 antibody-encoding nucleic acid refers to one or more nucleic acid molecules encoding a LAG-3 antibody-encoding chain or fragment thereof, including such nucleic acid molecules in a single vector or separate vectors, and present in Such nucleic acid molecules at one or more locations in a host cell.
  • the sequences are aligned for optimal comparison purposes (e.g., between the first and second amino acid sequences or nucleic acid sequences for optimal alignment. Gaps are introduced in one or both or non-homologous sequences can be discarded for comparison purposes).
  • the length of the reference sequences aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60% and even more preferably at least 70%, 80% , 90%, 100% of the reference sequence length.
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence, then the molecules are identical at that position.
  • Sequence comparisons and calculation of percent identity between two sequences can be accomplished using mathematical algorithms.
  • the Needlema and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm (at http://www.gcg.com) is used that has been integrated into the GAP program of the GCG software package available), using the Blossum 62 matrix or the PAM250 matrix and gap weights 16, 14, 12, 10, 8, 6, or 4 and length weights 1, 2, 3, 4, 5, or 6, to determine the distance between two amino acid sequences percent identity.
  • the GAP program in the GCG software package (available at http://www.gcg.com) is used, using the NWSgapdna.CMP matrix and gap weights 40, 50, 60, 70 or 80 and A length weight of 1, 2, 3, 4, 5, or 6 determines the percent identity between two nucleotide sequences.
  • a particularly preferred set of parameters (and one that should be used unless otherwise specified) is the Blossum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.
  • nucleic acid sequences and protein sequences described herein can be further used as "query sequences" to perform searches against public databases, eg, to identify other family member sequences or related sequences.
  • hybridizes under conditions of low stringency, moderate stringency, high stringency or very high stringency describes hybridization and washing conditions.
  • Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6, incorporated by reference. Aqueous and non-aqueous methods are described in this reference and either method can be used.
  • the specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions are at about 45°C in 6X sodium chloride/sodium citrate (SSC) followed by at least 50°C (for Low stringency conditions, the temperature of the wash can be increased to 55°C) twice in 0.2X SSC, 0.1% SDS; 2) medium stringency hybridization conditions are at about 45°C in 6X SSC followed by 60°C in One or more washes in 0.2X SSC, 0.1% SDS; 3) High stringency hybridization conditions are one or more washes in 6X SSC at about 45°C followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C and preferably 4) very high stringency hybridization conditions are one or more washes in 0.5M sodium phosphate, 7% SDS at 65°C followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. Very high stringency conditions (4) are the preferred conditions and the one that should be
  • composition refers to a composition that is in a form that allows the biological activity of the active ingredients contained therein to be effective and does not contain additional ingredients.
  • pharmaceutically acceptable carrier refers to diluents, adjuvants (eg, Freund's adjuvant (complete and incomplete), excipients, buffers or stabilizers, etc.) with which the active substance is administered.
  • adjuvants eg, Freund's adjuvant (complete and incomplete)
  • excipients eg, buffers or stabilizers, etc.
  • treating refers to slowing, interrupting, retarding, alleviating, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease. Desired therapeutic effects include, but are not limited to, preventing disease occurrence or recurrence, reducing symptoms, reducing any direct or indirect pathological consequences of disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating disease state, and relieving or improving prognosis.
  • the antibody molecules of the invention are used to delay disease progression or to slow disease progression.
  • prevention includes the inhibition of the occurrence or progression of a disease or disorder or symptoms of a particular disease or disorder.
  • subjects with a family history of cancer are candidates for preventive regimens.
  • prevention refers to the administration of a drug prior to the onset of signs or symptoms of cancer, particularly in subjects at risk of cancer.
  • an effective amount refers to that amount or dose of an antibody or composition of the invention which, after administration to the patient in single or multiple doses, produces the desired effect in a patient in need of treatment or prevention.
  • An effective amount can be readily determined by the attending physician, who is skilled in the art, by considering a variety of factors such as the species of mammal; weight, age, and general health; the specific disease involved; the degree or severity of the disease; the individual The patient's response; the particular antibody administered; the mode of administration; the bioavailability profile of the administered formulation; the chosen dosing regimen; and the use of any concomitant therapy.
  • a “therapeutically effective amount” refers to an amount effective to achieve the desired therapeutic result, at the required dose and for the required period of time.
  • a therapeutically effective amount of an antibody or antibody fragment or composition thereof may vary depending on factors such as the disease state, the age, sex and weight of the individual and the ability of the antibody or antibody portion to elicit a desired response in the individual.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody fragment or composition thereof are outweighed by the therapeutically beneficial effects.
  • a "therapeutically effective amount” preferably inhibits a measurable parameter (eg, tumor growth rate, tumor volume, etc.) by at least about 20%, more preferably at least about 40%, even more preferably at least about 50%, relative to an untreated subject, 60% or 70% and still more preferably at least about 80% or 90%.
  • a measurable parameter eg, tumor growth rate, tumor volume, etc.
  • the ability of a compound to inhibit a measurable parameter can be evaluated in an animal model system predictive of efficacy in human tumors.
  • prophylactically effective amount refers to an amount effective to achieve the desired prophylactic result, at the required dose and for the required period of time. Typically, a prophylactically effective amount will be less than a therapeutically effective amount because a prophylactic dose is administered in a subject prior to or at an earlier stage of the disease.
  • therapeutic agent encompasses any substance that is effective in preventing or treating tumors (eg, cancer) and infections (eg, chronic infections), including chemotherapeutic agents, cytotoxic agents, other antibodies, anti-infective agents, small molecules Drugs or immunomodulators.
  • immunomodulator refers to a natural or synthetic active agent or drug that inhibits or modulates an immune response.
  • the immune response can be a humoral response or a cellular response.
  • Immunomodulators include immune checkpoint molecular inhibitors and costimulatory molecular activators.
  • small molecule drug refers to low molecular weight organic compounds capable of modulating biological processes.
  • cytotoxic agent refers to a substance that inhibits or prevents cell function and/or causes cell death or destruction. Examples of cytotoxic agents are found in those disclosed in WO2015/153513, WO2016/028672 or WO2015/138920.
  • anti-infective active agent includes any molecule that specifically inhibits or eliminates the growth of microorganisms, such as viruses, bacteria, fungi, or protozoa, eg, parasites, at the concentration and interval of administration, but is not lethal to the host.
  • anti-infective active agent includes antibiotics, antibacterial agents, antiviral agents, antifungal agents, and antiprotozoal agents.
  • the anti-infective active agent is nontoxic to the host at the concentration and interval of administration.
  • combination product refers to a fixed or non-fixed combination or kit of parts for combined administration in one dosage unit form, wherein two or more therapeutic agents can be administered independently at the same time or at a certain time. Administration is administered separately at time intervals, especially when these time intervals allow the combined therapeutic agents to exhibit synergy, eg, a synergistic effect.
  • fixed combination refers to the simultaneous administration of an antibody of the invention and a combination partner (eg, other therapeutic agent, eg, anti-PD-1 antibody or anti-PD-L1 antibody) to a patient in the form of a single entity or dose.
  • non-fixed combination means that a LAG-3 antibody of the invention and a combination partner (eg, other therapeutic agent, eg, an anti-PD-1 antibody or an anti-PD-L1 antibody) are administered to a patient simultaneously, concurrently or sequentially as separate entities, There is no particular time limit, wherein such administration provides therapeutically effective levels of both therapeutic agents in the patient. The latter also applies to cocktail therapy, eg, the administration of three or more therapeutic agents.
  • the drug combination is a non-fixed combination.
  • combination therapy refers to the administration of two or more therapeutic agents to treat cancer or infection as described in the present disclosure.
  • administration includes co-administration of the therapeutic agents in a substantially simultaneous manner, eg, in a single capsule having a fixed ratio of active ingredients.
  • administration includes co-administration or separate administration or sequential administration of each active ingredient in multiple or separate containers (eg, tablets, capsules, powders, and liquids). Powders and/or liquids can be reconstituted or diluted to the desired dose prior to administration.
  • administering also includes administering each type of therapeutic agent at approximately the same time, or in a sequential manner at different times. In either case, the treatment regimen will provide the beneficial effect of the drug combination in the treatment of the disorders or conditions described herein.
  • vector refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked.
  • the term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of the host cell into which they have been introduced. Some vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors”.
  • host cell refers to a cell into which an exogenous polynucleotide has been introduced, including progeny of such cells.
  • Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom, regardless of the number of passages.
  • the progeny may not be identical in nucleic acid content to the parent cell, but may contain mutations. Included herein are mutant progeny screened or selected for the same function or biological activity in the originally transformed cell.
  • a host cell is any type of cellular system that can be used to produce the antibody molecules of the invention, including eukaryotic cells, eg, mammalian cells, insect cells, yeast cells; and prokaryotic cells, eg, E. coli cells.
  • Host cells include cultured cells and also include transgenic animals, transgenic plants, or cells within cultured plant or animal tissue.
  • tissue sample refers to a collection of cells, tissues or bodily fluids obtained from a patient or subject.
  • the source of a tissue or cell sample can be solid tissue like from a fresh, frozen and/or preserved organ or tissue sample or biopsy or biopsy; blood or any blood component; body fluids such as cerebrospinal fluid, amniotic fluid (amniotic fluid); ), peritoneal fluid (ascites), or interstitial fluid; cells from any time of pregnancy or development of the subject.
  • Tissue samples may contain compounds that are not naturally associated with tissue in nature, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, and the like.
  • tumor samples herein include, but are not limited to, tumor biopsies, fine needle aspirate, bronchial lavage fluid, pleural fluid (pleural fluid), sputum, urine, surgical specimens, circulating tumor cells, serum, plasma, circulating tumor cells plasma proteins in ascites fluid, primary cell cultures or cell lines derived from tumors or exhibiting tumor-like properties, and preserved tumor samples such as formalin-fixed, paraffin-embedded tumor samples, or frozen tumors sample.
  • package insert is used to refer to instructions for use typically contained in commercial packaging of therapeutic products, which contain information on indications, usage, dosage, administration, combination therapy, contraindications and/or warnings related to the use of such therapeutic products .
  • the antibody that specifically binds to LAG-3 of the present invention comprises a heavy chain variable region and a light chain variable region, wherein:
  • the heavy chain variable region comprises HCDR1 shown in SYGIS (SEQ ID NO: 31), or a variant of said HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; EIYPRSDNTYYNGKFKG (SEQ ID NO: 31) NO: 32), or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in RAFYYYGSNYYAMDY (SEQ ID NO: 33), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises LCDR1 shown in RSSQSIVHSNGDTYLE (SEQ ID NO: 34), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in KVSNRFS (SEQ ID NO: 35), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change;
  • the heavy chain variable region comprises HCDR1 shown in NYAMS (SEQ ID NO: 37), or a variant of said HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; TITYGTTYTFYSDNVKG (SEQ ID NO: 37) NO: 38), or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in GEYGSSFAY (SEQ ID NO: 39), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change;
  • the light chain variable region comprises LCDR1 as shown in KASQNVRTAVA (SEQ ID NO: 40), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in LASNRHT (SEQ ID NO: 41), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and LQHWNYPLT (S
  • variable region of the heavy chain comprises HCDR1 shown in DYAVS (SEQ ID NO: 43), or a variant of the HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; VVWGDGSTNYHSALIS (SEQ ID NO: 43) NO: 44) shown in HCDR2, or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in GGGGMDY (SEQ ID NO: 45), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises LCDR1 shown in RASSSVSYMH (SEQ ID NO: 46), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in ATSNLAS (SEQ ID NO: 47), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and QHYNTNPPT
  • variable region of the heavy chain comprises HCDR1 shown in DDYMH (SEQ ID NO: 49), or a variant of the HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; RIDPEDVETKYDPKFQG (SEQ ID NO: 49) NO:50), or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO:51), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises LCDR1 shown in KASENVGTYVS (SEQ ID NO: 52), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in GASNRYT (SEQ ID NO: 53), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and GQ
  • the heavy chain variable region comprises HCDR1 shown in DDYMH (SEQ ID NO: 49), or a variant of said HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; WIDPENGETEYASKFQG (SEQ ID NO: 49) NO: 55) shown in HCDR2, or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in FDY (SEQ ID NO: 56), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises LCDR1 as shown in KSSQSLLDSDGKTYLN (SEQ ID NO: 57), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in LVSKLDF (SEQ ID NO: 58), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change;
  • the heavy chain variable region comprises HCDR1 shown in NYGIS (SEQ ID NO: 60), or a variant of said HCDR1 with no more than 2 amino acid changes or no more than 1 amino acid change; EIYPRGGNTYYNGKFKG (SEQ ID NO: 60) NO: 61), or a variant of said HCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change; and HCDR3 shown in RAFYYFGSNYYAMDY (SEQ ID NO: 62), or a variant of said HCDR3 A variant with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises LCDR1 shown in RSSQSIVHSNGDTYLE (SEQ ID NO: 34), or no more than 2 amino acid changes of said LCDR1 or Variants with no more than 1 amino acid change; LCDR2 shown in KVSNRFS (SEQ ID NO: 35), or a variant of said LCDR2 with no more than 2 amino acid changes or no more than 1 amino acid change
  • amino acid change is an addition, deletion or substitution of an amino acid, eg, the amino acid change is a conservative amino acid substitution.
  • the CDRs are CDRs according to the Kabat numbering scheme.
  • the antibodies of the invention bind mammalian LAG-3, eg, human LAG-3, monkey LAG-3. In some embodiments, the LAG-3 antibodies of the invention bind to one or more extracellular domains of LAG-3.
  • the antibodies of the invention have one or more of the following properties:
  • Binds LAG-3 with high affinity eg, human LAG-3 and cynomolgus monkey LAG-3, eg, the KD for binding between the anti-LAG-3 antibody or antigen-binding fragment thereof and LAG -3 is about 10 -7 M to about 10-12 M, preferably, about 10-8 M to about 10-12 M, as measured by the ForteBio kinetic binding assay;
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises SYGIS (SEQ ID NO:31 HCDR1 shown in ); HCDR2 shown in EIYPRSDNTYYNGKFKG (SEQ ID NO: 32); and HCDR3 shown in RAFYYYGSNYYAMDY (SEQ ID NO: 33); the light chain variable region comprises RSSQSIVHSNGDTYLE (SEQ ID NO: 34) LCDR1 shown in KVSNRFS (SEQ ID NO: 35); LCDR3 shown in FQGSHVPWT (SEQ ID NO: 36).
  • SYGIS SEQ ID NO:31 HCDR1 shown in
  • HCDR2 shown in EIYPRSDNTYYNGKFKG
  • HCDR3 shown in RAFYYYGSNYYAMDY
  • the light chain variable region comprises RSSQSIVHSNGDTYLE (SEQ ID NO: 34)
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises NYAMS (SEQ ID NO:37 HCDR1 shown in ); HCDR2 shown in TITYGTTYTFYSDNVKG (SEQ ID NO: 38); and HCDR3 shown in GEYGSSFAY (SEQ ID NO: 39); the light chain variable region comprises KASQNVRTAVA (SEQ ID NO: 40) LCDR1 shown in LASNRHT (SEQ ID NO: 41); LCDR3 shown in LQHWNYPLT (SEQ ID NO: 42).
  • the heavy chain variable region comprises NYAMS (SEQ ID NO:37 HCDR1 shown in ); HCDR2 shown in TITYGTTYTFYSDNVKG (SEQ ID NO: 38); and HCDR3 shown in GEYGSSFAY (SEQ ID NO: 39); the light chain variable region comprises KASQNVRTAVA (SEQ ID NO: 40) LCDR
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises DYAVS (SEQ ID NO:43 HCDR1 represented by ); HCDR2 represented by VVWGDGSTNYHSALIS (SEQ ID NO: 44); and HCDR3 represented by GGGGMDY (SEQ ID NO: 45); the light chain variable region comprises RASSSVSYMH (SEQ ID NO: 46) LCDR1 shown in ATSNLAS (SEQ ID NO: 47); LCDR3 shown in QHYNTNPPTWT (SEQ ID NO: 48).
  • the heavy chain variable region comprises DYAVS (SEQ ID NO:43 HCDR1 represented by ); HCDR2 represented by VVWGDGSTNYHSALIS (SEQ ID NO: 44); and HCDR3 represented by GGGGMDY (SEQ ID NO: 45); the light chain variable region comprises RASSSVSYMH (SEQ ID NO: 46) LCDR1 shown in ATSN
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises DDYMH (SEQ ID NO: 49 HCDR1 shown in ); HCDR2 shown in RIX 1 PEDVETKYDPKFQG (SEQ ID NO: 64), preferably, wherein X 1 is D or N; and HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51);
  • the light chain variable region comprises LCDR1 shown by X 2 ASENVGTYVS (SEQ ID NO: 68), preferably, wherein X 2 is K or R; LCDR2 shown by X 3 ASX 4 RYT (SEQ ID NO: 69) , preferably; wherein X 3 is G or A; X 4 is N or T; and LCDR3 shown in GQSYSYPYT (SEQ ID NO: 54).
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises DDYMH (SEQ ID NO: HCDR1 shown in 49); HCDR2 shown in RIDPEDVETKYDPKFQG (SEQ ID NO: 50); and HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51); the light chain variable region comprises KASENVGTYVS (SEQ ID NO: 52) LCDR1 shown, LCDR2 shown by GASNRYT (SEQ ID NO:53), and LCDR3 shown by GQSYSYPYT (SEQ ID NO:54).
  • DDYMH SEQ ID NO: HCDR1 shown in 49
  • HCDR2 shown in RIDPEDVETKYDPKFQG SEQ ID NO: 50
  • HCDR3 shown in SFYSNYVNYFDQ
  • the light chain variable region comprises KASENVGTYVS (SEQ ID NO: 52
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises DDYMH (SEQ ID NO: HCDR1 shown in 49); HCDR2 shown in RIDPEDVETKYDPKFQG (SEQ ID NO: 50), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51); the light chain variable region comprises KASENVGTYVS (SEQ ID NO: 52).
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises DDYMH (SEQ ID NO: HCDR1 shown in 49); HCDR2 shown in RIDPEDVETKYDPKFQG (SEQ ID NO: 50), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51); the light chain variable region comprises RASENVGTYVS (SEQ ID NO: 65).
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises DDYMH (SEQ ID NO: HCDR1 shown in 49); HCDR2 shown in RIDPEDVETKYDPKFQG (SEQ ID NO: 50), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51); the light chain variable region comprises KASENVGTYVS (SEQ ID NO: 52).
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises DDYMH (SEQ ID NO: HCDR1 shown in 49); HCDR2 shown in RINPEDVETKYDPKFQG (SEQ ID NO: 63), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51); the light chain variable region comprises KASENVGTYVS (SEQ ID NO: 52).
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises DDYMH (SEQ ID NO: HCDR1 shown in 49); HCDR2 shown in RINPEDVETKYDPKFQG (SEQ ID NO: 63), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51); the light chain variable region comprises KASENVGTYVS (SEQ ID NO: 52).
  • LCDR1 shown by AASNRYT SEQ ID NO: 66
  • LCDR2 shown by GQSYSYPYT SEQ ID NO: 54
  • LCDR3 shown by GQSYSYPYT (SEQ ID NO: 54).
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises DDYMH (SEQ ID NO: HCDR1 shown in 49); HCDR2 shown in RINPEDVETKYDPKFQG (SEQ ID NO: 63), HCDR3 shown in SFYSNYVNYFDQ (SEQ ID NO: 51); the light chain variable region comprises KASENVGTYVS (SEQ ID NO: 52).
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises DDYMH (SEQ ID NO:49 HCDR1 shown in ); HCDR2 shown in WIDPENGETEYASKFQG (SEQ ID NO: 55); and HCDR3 shown in FDY (SEQ ID NO: 56); the light chain variable region comprises KSSQSLLDSDGKTYLN (SEQ ID NO: 57) LCDR1 shown in LVSKLDF (SEQ ID NO: 58); LCDR2 shown in WQGTHFPQT (SEQ ID NO: 59); or
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises NYGIS (SEQ ID NO:60 HCDR1 represented by ); HCDR2 represented by EIYPRGGNTYYNGKFKG (SEQ ID NO:61); and HCDR3 represented by RAFYYFGSNYYAMDY (SEQ ID NO:62); the light chain variable region comprises the LCDR1 shown in KVSNRFS (SEQ ID NO: 35); LCDR3 shown in FQGSHVPWT (SEQ ID NO: 36).
  • the heavy chain variable region comprises NYGIS (SEQ ID NO:60 HCDR1 represented by ); HCDR2 represented by EIYPRGGNTYYNGKFKG (SEQ ID NO:61); and HCDR3 represented by RAFYYFGSNYYAMDY (SEQ ID NO:62); the light chain variable region comprises the LCDR1 shown in KVSNRFS (SEQ ID NO
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising N-FR1-CDR1- Heavy chain variable region and light chain variable region of FR2-CDR2-FR3-CDR3-FR4-C, wherein the 6 CDRs of each antibody are as defined above, and the FRs are FRs derived from human antibodies.
  • the heavy chain variable region of a humanized LAG-3 antibody or antigen-binding fragment thereof comprises the amino acid sequences QVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO:80), EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO:81), EVQLVQSGAEVKKPGASVKVSCKASGYTIK (SEQ ID NO:81) ID NO:82), FR1 of EVQLVQSGAEVKKPGASVKVSCKASGVNFT (SEQ ID NO:83) or EVQLVQSGAEVKKPGASVKVSCKASGVNIK (SEQ ID NO:84), FR2 containing the amino acid sequence WVRQAPGQGLEWMG (SEQ ID NO:85) or WVRQAPGQGLEWIG (SEQ ID NO:86), FR3 of amino acid sequence RVTTRDTSTSTVYMELSSLRSEDTAVYYCAR (SEQ ID NO:87
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO:80, FR2 containing amino acid sequence of SEQ ID NO:85, and FR2 containing amino acid sequence SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO:80, FR2 containing amino acid sequence of SEQ ID NO:85, and FR2 containing amino acid sequence SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO: 81, FR2 containing amino acid sequence of SEQ ID NO: 86, containing FR3 of amino acid sequence SEQ ID NO: 87 and FR4 containing amino acid sequence SEQ ID NO: 90;
  • the light chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and FR1 containing the amino acid sequence SEQ ID NO:70, FR2 containing the amino acid sequence SEQ ID NO:73, FR3 containing the amino acid sequence SEQ ID NO:76, and FR4
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO: 81, FR2 containing amino acid sequence of SEQ ID NO: 86, containing FR3 of amino acid sequence SEQ ID NO: 87 and FR4 containing amino acid sequence SEQ ID NO: 90;
  • the light chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and FR1 containing the amino acid sequence SEQ ID NO:70, FR2 containing the amino acid sequence SEQ ID NO:72, FR3 containing the amino acid sequence SEQ ID NO:76, and FR4
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO:81, FR2 containing amino acid sequence of SEQ ID NO:85, and FR2 containing amino acid sequence SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO:81, FR2 containing amino acid sequence of SEQ ID NO:85, and FR2 containing amino acid sequence SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO: 81, FR2 containing amino acid sequence of SEQ ID NO: 86, containing FR3 of amino acid sequence SEQ ID NO: 87 and FR4 containing amino acid sequence SEQ ID NO: 90;
  • the light chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and FR1 containing the amino acid sequence SEQ ID NO:71, FR2 containing the amino acid sequence SEQ ID NO:74, FR3 containing the amino acid sequence SEQ ID NO:77, and FR4
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO:81, FR2 containing amino acid sequence of SEQ ID NO:85, and FR2 containing amino acid sequence SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO:81, FR2 containing amino acid sequence of SEQ ID NO:85, and FR2 containing amino acid sequence SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO:81, FR2 containing amino acid sequence of SEQ ID NO:85, and FR2 containing amino acid sequence SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO:81, FR2 containing amino acid sequence of SEQ ID NO:85, and FR2 containing amino acid sequence SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from N-terminal to C-terminal, namely FR1, FR2, FR3 and FR4, and contains FR1 of amino acid sequence SEQ ID NO:81, FR2 containing amino acid sequence of SEQ ID NO:85, and FR2 containing amino acid sequence SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains FR1 of the amino acid sequence SEQ ID NO:82, FR2 of the amino acid sequence of SEQ ID NO:85, and FR2 of the amino acid sequence of SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains FR1 of the amino acid sequence SEQ ID NO:82, FR2 of the amino acid sequence of SEQ ID NO:85, and FR2 of the amino acid sequence of SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains FR1 of the amino acid sequence SEQ ID NO:82, FR2 of the amino acid sequence of SEQ ID NO:85, and FR2 of the amino acid sequence of SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains FR1 of the amino acid sequence SEQ ID NO:82, FR2 of the amino acid sequence of SEQ ID NO:85, and FR2 of the amino acid sequence of SEQ ID NO:85.
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains the FR1 of the amino acid sequence of SEQ ID NO:83, the FR2 of the amino acid sequence of SEQ ID NO:85, the FR3 of amino acid sequence SEQ ID NO: 87 and FR4 containing amino acid sequence SEQ ID NO: 90;
  • the light chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and FR1 containing the amino acid sequence SEQ ID NO:70, FR2 containing the amino acid sequence SEQ ID NO:73, FR3 containing the amino acid sequence SEQ ID NO:76, and
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains the FR1 of the amino acid sequence of SEQ ID NO:83, the FR2 of the amino acid sequence of SEQ ID NO:85, the The FR3 of the amino acid sequence SEQ ID NO:87 and the FR4 containing the amino acid sequence of SEQ ID NO:90;
  • the light chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and FR1 containing the amino acid sequence SEQ ID NO:70, FR2 containing the amino acid sequence SEQ ID NO:72, FR3 containing the amino acid sequence SEQ ID NO
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains the FR1 of the amino acid sequence of SEQ ID NO:83, the FR2 of the amino acid sequence of SEQ ID NO:85, the FR3 of amino acid sequence SEQ ID NO: 87 and FR4 containing amino acid sequence SEQ ID NO: 90;
  • the light chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and FR1 containing the amino acid sequence SEQ ID NO:71, FR2 containing the amino acid sequence SEQ ID NO:74, FR3 containing the amino acid sequence SEQ ID NO:77, and
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains the FR1 of the amino acid sequence of SEQ ID NO:83, the FR2 of the amino acid sequence of SEQ ID NO:85, the FR3 of amino acid sequence SEQ ID NO: 87 and FR4 containing amino acid sequence SEQ ID NO: 90;
  • the light chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and FR1 containing the amino acid sequence SEQ ID NO:71, FR2 containing the amino acid sequence SEQ ID NO:75, FR3 containing the amino acid sequence SEQ ID NO:78, and
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains the FR1 of the amino acid sequence of SEQ ID NO:84, the FR2 of the amino acid sequence of SEQ ID NO:86, the FR3 of amino acid sequence SEQ ID NO: 89 and FR4 containing amino acid sequence SEQ ID NO: 90;
  • the light chain variable region comprises four framework regions from N-terminus to C-terminus, namely FR1, FR2, FR3 and FR4, and FR1 containing the amino acid sequence SEQ ID NO:70, FR2 containing the amino acid sequence SEQ ID NO:73, FR3 containing the amino acid sequence SEQ ID NO:76, and FR
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains the FR1 of the amino acid sequence of SEQ ID NO:84, the FR2 of the amino acid sequence of SEQ ID NO:86, the FR3 of amino acid sequence SEQ ID NO: 89 and FR4 containing amino acid sequence SEQ ID NO: 90;
  • the light chain variable region comprises four framework regions from N-terminus to C-terminus, namely FR1, FR2, FR3 and FR4, and FR1 containing the amino acid sequence SEQ ID NO:70, FR2 containing the amino acid sequence SEQ ID NO:72, FR3 containing the amino acid sequence SEQ ID NO:76, and FR
  • the antibody or antigen-binding fragment of the invention that specifically binds LAG-3 is a humanized LAG-3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain
  • the chain variable region comprises four framework regions from the N-terminus to the C-terminus, namely FR1, FR2, FR3 and FR4, and contains the FR1 of the amino acid sequence of SEQ ID NO:84, the FR2 of the amino acid sequence of SEQ ID NO:86, the FR3 of amino acid sequence SEQ ID NO: 89 and FR4 containing amino acid sequence SEQ ID NO: 90;
  • the light chain variable region comprises four framework regions from N-terminus to C-terminus, namely FR1, FR2, FR3 and FR4, and FR1 containing the amino acid sequence SEQ ID NO:71, FR2 containing the amino acid sequence SEQ ID NO:75, FR3 containing the amino acid sequence SEQ ID NO:76, and FR
  • an antibody or antigen-binding fragment of the invention that specifically binds LAG-3 comprises or consists of a heavy chain variable region and a light chain variable region of the following sequences:
  • any paired heavy chain variable region selected from the group consisting of SEQ ID NOs: 1/2, 3/4, 5/6, 7/8, 9/10, 11/12, 15/16 and 15/17 sequence/light chain variable region sequence;
  • the antibodies of the invention have an Fc region, eg, an Fc region from an IgG, eg, IgGl, IgG2, IgG3, or IgG4. In some embodiments, the Fc region is from IgG4. In some embodiments, the Fc region is from human IgG4.
  • the amino acid changes described herein include amino acid substitutions, insertions or deletions.
  • the amino acid changes described herein are amino acid substitutions, preferably conservative substitutions.
  • the amino acid changes described herein occur in regions outside the CDRs (eg, in FRs). More preferably, the amino acid changes described in the present invention occur in regions outside the heavy chain variable region and the light chain variable region.
  • the substitutions are conservative substitutions. Conservative substitution refers to the substitution of one amino acid by another amino acid within the same class, e.g., substitution of an acidic amino acid by another acidic amino acid, substitution of a basic amino acid by another basic amino acid, or substitution of a neutral amino acid by another neutral amino acid replace. Exemplary substitutions are shown in Table 1 below:
  • substitutions Ala(A) Val; Leu; Ile Val Arg(R) Lys; Gln; Asn Lys Asn(N) Gln; His; Asp, Lys; Arg Gln Asp(D) Glu; Asn Glu Cys(C) Ser; Ala Ser Gln(Q) Asn;Glu Asn Glu(E) Asp;Gln Asp Gly(G) Ala Ala His(H) Asn; Gln; Lys; Arg Arg Ile(I) Leu, Val; Met; Ala; Phe; Norleucine Leu Leu(L) Norleucine; Ile; Val; Met; Ala; Phe Ile Lys(K) Arg; Gln; Asn Arg Met(M) Leu; Phe; Ile Leu
  • the LAG-3 antibodies provided herein are altered to increase or decrease the degree of glycosylation thereof. Glycosylation sites are added or deleted to the LAG-3 antibody by altering the amino acid sequence to create or remove one or more glycosylation sites.
  • the LAG-3 antibody comprises an Fc region
  • the carbohydrate attached to the Fc region can be altered.
  • modifications to remove unwanted glycosylation sites are advantageous, such as removal of fucose moieties to enhance antibody-dependent cellular cytotoxicity (ADCC) function.
  • ADCC antibody-dependent cellular cytotoxicity
  • galactosylation modifications can be made to modulate complement-dependent cytotoxicity (CDC).
  • one or more amino acid modifications can be introduced into the Fc region of the LAG-3 antibodies provided herein, thereby generating Fc region variants, in order to enhance, for example, the treatment of cancer or infectious diseases by the antibodies of the invention effectiveness.
  • the present invention provides nucleic acids encoding any of the above LAG-3 antibodies, or antigen-binding fragments thereof, or any chain thereof.
  • a vector comprising the nucleic acid is provided.
  • the vector is an expression vector.
  • a host cell comprising the nucleic acid or the vector is provided.
  • the host cell is eukaryotic.
  • the host cell is selected from yeast cells, mammalian cells (eg, CHO cells or 293 cells) or other cells suitable for the production of antibodies or antigen-binding fragments thereof.
  • the host cell is prokaryotic.
  • the nucleic acid of the present invention comprises a nucleic acid encoding an amino acid sequence selected from any one of SEQ ID NOs: 1-12, 15-28, or a nucleic acid encoding an amino acid sequence selected from any one of SEQ ID NOs: 1-12, 15-28
  • a stated amino acid sequence has an amino acid sequence of at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.
  • the present invention also encompasses nucleic acids that hybridize under stringent conditions to nucleic acids that hybridize under stringent conditions or that encode polypeptide sequences having one or more amino acid substitutions (eg, conservative substitutions), deletions or insertions compared to nucleic acids comprising encoding selected
  • a nucleic acid comprising a nucleic acid sequence selected from the amino acid sequence shown in any one of SEQ ID NOs: 1-12, 15-28;
  • the amino acid sequence has at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity of the nucleic acid sequence of the nucleic acid sequence of the amino acid sequence.
  • one or more vectors are provided comprising the nucleic acid.
  • the vector is an expression vector, such as a eukaryotic expression vector.
  • Vectors include, but are not limited to, viruses, plasmids, cosmids, lambda phage, or yeast artificial chromosomes (YACs).
  • YACs yeast artificial chromosomes
  • the vector is a pCDNA3.1 vector.
  • the expression vector can be transfected or introduced into a suitable host cell.
  • Various techniques can be used to achieve this, eg, protoplast fusion, calcium phosphate precipitation, electroporation, transduction of retroviruses, viral transfection, biolistic, lipid-based transfection, or other conventional techniques.
  • protoplast fusion cells are grown in culture medium and screened for appropriate activity. Methods and conditions for culturing the transfected cells produced and for recovering the antibody molecules produced are known to those skilled in the art and can be based on methods known in this specification and in the prior art, depending on the particular expression vector used and Mammalian host cell modification or optimization.
  • cells that have stably incorporated DNA into their chromosomes can be selected by introducing one or more markers that allow selection of transfected host cells. Markers can, for example, provide prototrophy, biocidal resistance (eg, antibiotics), or heavy metal (eg, copper) resistance, etc. to an auxotrophic host.
  • the selectable marker gene can be introduced into the same cell by direct ligation to the DNA sequence to be expressed or by co-transformation. Additional elements may also be required for optimal mRNA synthesis. These elements can include splicing signals, as well as transcriptional promoters, enhancers, and termination signals.
  • host cells comprising the polynucleotides of the present invention are provided.
  • host cells comprising the expression vectors of the present invention are provided.
  • the host cell is selected from yeast cells, mammalian cells, or other cells suitable for producing antibodies. Suitable host cells include prokaryotic microorganisms such as E. coli. Host cells can also be eukaryotic microorganisms such as filamentous fungi or yeast, or various eukaryotic cells such as insect cells and the like. Vertebrate cells can also be used as hosts. For example, mammalian cell lines engineered for growth in suspension can be used.
  • Examples of useful mammalian host cell lines include SV40 transformed monkey kidney CV1 line (COS-7); human embryonic kidney lines (HEK 293 or 293F cells), 293 cells, baby hamster kidney cells (BHK), monkey kidney cells ( CV1), African green monkey kidney cells (VERO-76), human cervical cancer cells (HELA), canine kidney cells (MDCK), Buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), Chinese hamster ovary cells (CHO cells), CHOS cells, NSO cells, myeloma cell lines such as Y0, NSO, P3X63 and Sp2/0, etc.
  • the host cells are CHO cells or 293 cells.
  • the invention provides a method of making a LAG-3 antibody, wherein the method comprises culturing the nucleic acid comprising the LAG-3 antibody under conditions suitable for expression of the nucleic acid encoding the LAG-3 antibody or a host cell containing an expression vector for the nucleic acid, and optionally the LAG-3 antibody isolated. In a certain embodiment, the method further comprises recovering the LAG-3 antibody from the host cell (or host cell culture medium).
  • nucleic acid encoding the LAG-3 antibody of the invention is first isolated and inserted into a vector for further cloning and/or expression in host cells.
  • Such nucleic acids are readily isolated and sequenced using routine procedures, eg, by using oligonucleotide probes capable of binding specifically to nucleic acids encoding LAG-3 antibodies of the invention.
  • Antibodies of the invention prepared as described herein can be purified by known prior art techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like.
  • the actual conditions used to purify a particular protein will also depend on factors such as net charge, hydrophobicity, hydrophilicity, etc., and these will be apparent to those skilled in the art.
  • the purity of the antibodies of the invention can be determined by any of a variety of well-known analytical methods, including size exclusion chromatography, gel electrophoresis, high performance liquid chromatography, and the like.
  • LAG-3 antibodies provided herein can be identified, screened, or characterized for their physical/chemical properties and/or biological activity by a variety of assays known in the art.
  • the antibodies of the invention are tested for their antigen-binding activity, eg, by known methods such as ELISA, Western blotting, and the like.
  • Binding to LAG-3 can be determined using methods known in the art, exemplary methods are disclosed herein. In some embodiments, SPR or ForteBio kinetic binding assays are used to determine binding of an antibody of the invention to LAG-3.
  • the present invention also provides assays for identifying biologically active LAG-3 antibodies.
  • Biological activities may include, for example, binding to cell surface LAG-3 (eg, human LAG-3, monkey LAG-3), binding to LAG-3/MHC class II molecules, or inhibition of binding of LAG-3/FGL-1 role, etc.
  • Cells for use in any of the above in vitro assays include cell lines that naturally express LAG-3 or are engineered to express LAG-3.
  • the LAG-3 cell line engineered to express LAG-3 is a cell line that does not normally express LAG-3 and expresses LAG-3 after transfection of DNA encoding LAG-3 into the cells.
  • the anti-LAG-3 humanized antibody hz7F10 of the invention specifically binds human LAG-3 protein with an affinity (K D ) of about 4.17E- 11M, while the control antibody BMS-986016 binds human LAG-3 protein with an affinity (KD) of about 1.61E -10M. Therefore, the LAG-3 antibody of the present invention can specifically bind to the LAG-3 protein with high affinity.
  • the anti-LAG-3 humanized antibody hz7F10 of the present invention can effectively bind human LAG-3 recombinant protein with a median effective binding concentration (EC50) value of about 0.034 as measured by an ELISA assay nM.
  • EC50 median effective binding concentration
  • the anti-LAG-3 humanized antibody hz7F10 of the present invention can effectively bind to the human LAG-3 protein on the cell surface, as measured by FACS, with a half effective binding concentration (EC50) value of about 1.6 nM, which is comparable to the binding level of the control antibody BMS-986016 (EC50: 1.5 nM) to human LAG-3 protein on the cell surface.
  • EC50 half effective binding concentration
  • the anti-LAG-3 humanized antibody hz7F10 of the present invention can specifically block the binding of cell surface HLA to recombinant LAG-3 protein, as measured by FACS method, and its corresponding half effective inhibitory concentration
  • the IC50 value was 4.8 nM, and the blocking ability was better than that of the control antibody BMS-986016 (IC50: 9.9 nM).
  • the anti-LAG-3 humanized antibody hz7F10 of the invention is capable of blocking the binding of human LAG-3 to FGL-1, as measured by an ELISA assay, with a corresponding half effective inhibitory concentration IC50 value was 0.038nM, which was comparable to the blocking activity of the control antibody BMS-986016 (IC50: 0.038nM).
  • the anti-LAG-3 humanized antibody hz7F10 of the present invention has good in vivo efficacy in mice as determined by experimental animal models.
  • the anti-LAG-3 humanized antibody hz7F10 of the present invention has better anti-tumor efficacy than the control antibody BMS-986016, and the body weight of animals in each experimental group increased steadily without significant toxic effects.
  • the present invention provides compositions comprising any of the LAG-3 antibodies described herein or immunoconjugates thereof, preferably the compositions are pharmaceutical compositions.
  • the composition further comprises a pharmaceutically acceptable carrier.
  • a composition eg, a pharmaceutical composition
  • the composition is used to prevent or treat tumors.
  • the tumor is cancer.
  • the compositions are used to prevent or treat infections, eg, chronic infections, eg, bacterial infections, viral infections, fungal infections, protozoal infections, and the like.
  • compositions comprising LAG-3 antibodies or immunoconjugates thereof and/or compositions (including pharmaceutical compositions or medicaments) comprising polynucleotides encoding LAG-3 antibodies preparation).
  • compositions may also contain suitable pharmaceutically acceptable carriers such as those known in the art, pharmaceutically acceptable excipients, including buffers.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • Pharmaceutically acceptable carriers suitable for use in the present invention may be sterile liquids such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is the preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerin , propylene, glycol, water, ethanol, etc. See also "Handbook of Pharmaceutical Excipients", Fifth Edition, R.C. Rowe, P.J. Seskey and S.C. Owen, Pharmaceutical Press, London, Chicago, for the use of excipients and their uses.
  • the compositions may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents, if desired.
  • compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations and the like.
  • Oral formulations may contain standard pharmaceutical carriers and/or excipients, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, saccharin.
  • the compounds described herein can be prepared by mixing an antibody of the invention of the desired purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences, 16th Ed., Osol, A. ed. (1980)).
  • the pharmaceutical formulation of the LAG-3 antibody is preferably in the form of a lyophilized formulation or an aqueous solution.
  • compositions or formulations of the present invention may also contain more than one active ingredient required for the particular indication being treated, preferably those having complementary activities that do not adversely affect each other.
  • active ingredients or anti-infective active ingredients such as chemotherapeutic agents, cytotoxic agents, other antibodies, anti-infective active agents, small molecule drugs or immunomodulatory agents such as anti-PD-1 antibodies, anti- PD-L1 antibody, etc.
  • the active ingredients are suitably combined in amounts effective for the intended use.
  • sustained release formulations can be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the antibodies of the invention in the form of shaped articles such as films or microcapsules.
  • the invention also provides a combination product comprising an antibody or antigen-binding fragment thereof of the invention, or an immunoconjugate thereof, and one or more other therapeutic agents (eg, chemotherapeutic agents, other antibodies, cytotoxic agents, anti-infective agents, small molecule drugs or immunomodulators, etc.).
  • other therapeutic agents eg, chemotherapeutic agents, other antibodies, cytotoxic agents, anti-infective agents, small molecule drugs or immunomodulators, etc.
  • other antibodies such as anti-PD-1 antibodies, anti-PD-L1 antibodies.
  • the combination product is used to prevent or treat tumors.
  • the tumor is cancer or the like.
  • the combination product is used to prevent or treat an infection, eg, a chronic infection, eg, bacterial infection, viral infection, fungal infection, protozoal infection, and the like.
  • the two or more components of the combination product may be administered to the subject in combination sequentially, separately, or simultaneously.
  • kits comprising the antibodies, pharmaceutical compositions, or combination products of the present invention, and optional package inserts directing administration.
  • the present invention also provides a pharmaceutical product comprising the antibody, pharmaceutical composition combination product of the invention, optionally further comprising a package insert to direct administration.
  • the present invention relates to a method of modulating an immune response in an individual.
  • the method comprises administering to a subject an effective amount of a LAG-3 antibody disclosed herein, or a pharmaceutical composition or combination comprising the LAG-3 antibody, thereby modulating an immune response in the subject.
  • a therapeutically effective amount of a LAG-3 antibody or pharmaceutical composition or combination disclosed herein restores, enhances, stimulates or increases an immune response in a subject.
  • the present invention relates to methods of inhibiting the activity of LAG-3, blocking the binding of LAG-3 to MHC class II molecules, blocking the binding of LAG-3 to FGL-1 molecules in an individual, the methods comprising An effective amount of a LAG-3 antibody disclosed herein, or a pharmaceutical composition or combination product comprising the same, is administered to the subject.
  • the present invention relates to a method of preventing or treating a tumor (eg, cancer) in a subject, the method comprising administering to the subject an effective amount of a LAG-3 antibody disclosed herein, or a pharmaceutical combination comprising the same substance or combination product.
  • a tumor eg, cancer
  • the tumor is an immune escaped tumor.
  • the present invention relates to a method of preventing or treating an infectious disease in a subject, the method comprising administering to the subject an effective amount of a LAG-3 antibody disclosed herein or a pharmaceutical composition comprising the same or Combination products.
  • the invention in another aspect, relates to a method of inducing antibody-dependent cell-mediated cytotoxicity in a subject, the method comprising administering to the subject an effective amount of a LAG-3 antibody disclosed herein or comprising the same pharmaceutical compositions or combination products.
  • the subject can be a mammal, eg, a primate, preferably a higher primate, eg, a human (eg, a patient having or at risk of having a disease described herein).
  • the subject has or is at risk of having a disease described herein (eg, a tumor or an infectious disease as described herein).
  • the subject receives or has received other treatments, such as chemotherapy treatment and/or radiation therapy.
  • the subject is or is at risk of being immunocompromised due to the infection.
  • tumors eg, cancers, described herein, include, but are not limited to, solid tumors, hematological cancers, soft tissue tumors, and metastatic lesions.
  • solid tumors include malignancies, eg, sarcomas and carcinomas (including adenocarcinomas and squamous cell carcinomas) of multiple organ systems, such as those that invade the liver, lung, breast, lymph, gastrointestinal tract (eg, colon), reproductive Those of the urinary tract (eg, kidney, bladder epithelial cells), prostate and pharynx.
  • Adenocarcinomas include malignancies such as most colon cancers, rectal cancers, renal cell carcinomas, liver cancers, non-small cell lung cancers in lung cancers, small bowel cancers, and esophageal cancers.
  • Squamous cell carcinoma includes malignant tumors such as those in the lung, esophagus, skin, head and neck region, mouth, anus, and cervix.
  • the cancer is melanoma, eg, advanced melanoma.
  • the cancer is renal cell carcinoma. Metastatic lesions of the aforementioned cancers can also be treated or prevented using the methods and compositions of the present invention.
  • Non-limiting examples of preferred cancers for treatment include lymphoma (eg, diffuse large B-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma), breast cancer (eg, metastatic breast cancer), Liver cancer (eg, hepatocellular carcinoma (HCC)), lung cancer (eg, non-small cell lung cancer (NSCLC), eg, stage IV or recurrent non-small cell lung cancer, NSCLC adenocarcinoma, or NSCLC squamous cell carcinoma), myeloma (eg, multiple myeloma), leukemia (eg, chronic myeloid leukemia), skin cancer (eg, melanoma (eg, stage III or IV melanoma) or Merkel cell carcinoma), head and neck cancer (eg, head and neck squamous cell carcinoma) Squamous cell carcinoma (HNSCC), myelodysplastic syndrome, bladder cancer (eg, transitional cell carcinoma), kidney cancer
  • the disease is a disease with elevated (nucleic acid or protein) levels of LAG-3.
  • the tumor is a tumor, such as cancer, that can be inhibited by inhibiting the binding of LAG-3 to MHC class II molecules and/or FGL-1 molecules.
  • the tumor or infection is a disease that would benefit from inhibition of LAG-3 at the nucleic acid or protein level.
  • the infection is acute or chronic.
  • the chronic infection is a persistent infection, a latent infection, or a slow infection.
  • the chronic infection is caused by a pathogen selected from bacteria, viruses, fungi and protozoa.
  • an antibody of the invention delays the onset of the disorder and/or symptoms associated with the disorder.
  • the methods of prevention or treatment described herein further comprise administering to said subject or individual a combination of a LAG-3 antibody or pharmaceutical composition or combination product disclosed herein, and one or more other therapies, For example, therapeutic modalities and/or other therapeutic agents.
  • treatment modalities include surgery (eg, tumor resection); radiation therapy (eg, external particle beam therapy, which involves three-dimensional conformal radiation therapy in which the irradiation area is designed), localized irradiation (eg, directed to a preselected target) or organ irradiation) or focused irradiation), etc.
  • the focused irradiation may be selected from stereotactic radiosurgery, segmented stereotactic radiosurgery, and intensity-modulated radiotherapy.
  • Focused irradiation may have a radiation source selected from particle beams (protons), cobalt-60 (photons) and linear accelerators (X-rays), eg, as described in WO 2012/177624.
  • Radiation therapy can be administered by one or a combination of several methods including, but not limited to, external particle beam therapy, internal radiation therapy, implant irradiation, stereotactic radiosurgery, systemic radiation therapy, radiotherapy, and permanent or transient Interstitial brachytherapy.
  • the therapeutic agent is selected from chemotherapeutic agents, cytotoxic agents, other antibodies, anti-infective agents, small molecule drugs, or immunomodulatory agents (eg, activators of co-stimulatory molecules or inhibitors of immune checkpoint molecules).
  • Exemplary other antibodies include, but are not limited to, inhibitors of immune checkpoint molecules (eg, anti-PD-1, anti-PD-L1, anti-TIM-3, or anti-CEACAM); antibodies that stimulate immune cells (eg, agonistic GITR antibodies) or CD137 antibody) and so on.
  • the other antibodies are selected from anti-PD-1 antibodies and/or anti-PD-L1 antibodies.
  • the anti-PD-1 antibody is Nivolumab of Bristol-Myers Squibb (BMS) and Pembrolizumab of Merck; the anti-PD-L1
  • BMS Bristol-Myers Squibb
  • the antibodies are atezolizumab developed by Roche, avelumab developed by Merck KGaA in Germany and Pfizer in the United States, and durvalumab developed by AstraZeneca.
  • the immunomodulatory agent is an agonist of a costimulatory molecule.
  • the agonist of the costimulatory molecule is selected from the group consisting of agonists (eg, agonistic antibodies or antigen-binding fragments thereof, or soluble fusions) of the following molecules: OX40, CD2, CD27, CD28, CDS, ICAM-1 , LFA-1(CD11a/CD18), ICOS(CD278), 4-1BB(CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 body.
  • Combination therapy of the present invention encompasses combined administration (wherein two or more therapeutic agents are contained in the same formulation or separate formulations) and separate administration.
  • administration of the antibodies or immunoconjugates, etc. of the invention may be performed before, concurrently with, and/or after administration of the other therapy.
  • the administration of the LAG-3 antibody and the administration of the other therapy are within about one month of each other, or within about one, two or three weeks, or about 1, 2, 3, occur within 4, 5, or 6 days.
  • the antibodies of the invention can be administered by any suitable method, including parenteral, intrapulmonary, and intranasal administration, and, if desired for topical treatment, Intralesional administration.
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration.
  • administration may be by any suitable route, eg, by injection, eg, intravenously or subcutaneously.
  • Various dosing schedules are contemplated herein, including, but not limited to, single administration or multiple administrations at multiple time points, bolus administration, and pulse infusion.
  • the appropriate dosage of the antibodies of the invention (when used alone or in combination with one or more other therapeutic agents) will depend on the type of disease to be treated, the type of LAG-3 antibody, the severity of the disease sex and course, whether the LAG-3 antibody was administered for prophylactic or therapeutic purposes, previous treatments, the patient's clinical history and response to the LAG-3 antibody, and the judgment of the attending physician.
  • the LAG-3 antibody is suitably administered to the patient in a single treatment or over a series of treatments. Dosages and treatment regimens of LAG-3 antibodies can be determined by the skilled artisan.
  • compositions or combination products of the invention can be used in place of LAG-3 antibodies for any of the prophylaxis or treatments described above.
  • any of the LAG-3 antibodies provided herein can be used to detect the presence of LAG-3 in a biological sample.
  • the term "detection" includes quantitative or qualitative detection, and exemplary detection methods may involve immunohistochemistry, immunocytochemistry, flow cytometry (eg, FACS), magnetic beads complexed with antibody molecules, ELISA assays Law.
  • the biological sample is blood, serum, or other bodily fluid sample of biological origin.
  • the biological sample comprises cells or tissues.
  • the biological sample is from a hyperproliferative or cancerous lesion.
  • LAG-3 antibodies for use in a diagnostic or detection method are provided.
  • a method of detecting the presence of LAG-3 in a biological sample comprises detecting the presence of LAG-3 protein in a biological sample.
  • the LAG-3 is human LAG-3.
  • the method comprises contacting a biological sample with a LAG-3 antibody as described herein under conditions that allow binding of the LAG-3 antibody to LAG-3, and detecting the presence of LAG-3 antibody and LAG-3 Whether a complex is formed between 3. Formation of the complex indicates the presence of LAG-3.
  • the method can be in vitro or in vivo.
  • the LAG-3 antibody is used to select subjects suitable for treatment with the LAG-3 antibody, eg, wherein LAG-3 is the biomarker used to select the subject.
  • the antibodies of the invention can be used to diagnose cancer or tumors, eg, to evaluate (eg, monitor) a subject for treatment or progression of a disease described herein (eg, a hyperproliferative or cancerous disease), its diagnosis and/or or installment.
  • labeled LAG-3 antibodies are provided.
  • Labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent labels, chromophore labels, electron-dense labels, chemiluminescent labels, and radioactive labels), and moieties that are detected indirectly, such as enzymes or ligands, for example, through enzymatic reactions or molecular interactions.
  • Exemplary labels include, but are not limited to, radioisotopes32P, 14C , 125I , 3H and131I , fluorophores such as rare earth chelates or fluorescein and derivatives thereof, rhodamine and derivatives thereof, dansyl ( dansyl), umbelliferone, luceriferase, eg, firefly luciferase and bacterial luciferase (US Pat. No.
  • luciferin 2,3-dihydrophthalazine dihydrogen Ketones, horseradish peroxidase (HR), alkaline phosphatase, beta-galactosidase, glucoamylase, lysozyme, carbohydrate oxidase, e.g., glucose oxidase, galactose oxidase, and glucose -6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, and enzymes that utilize hydrogen peroxide dye precursors such as HR, lactoperoxidase, or microperoxidase ), biotin/avidin, spin tags, phage tags, stabilized free radicals, etc.
  • HR horseradish peroxidase
  • alkaline phosphatase beta-galactosidase
  • glucoamylase lysozyme
  • carbohydrate oxidase e.g., glucose
  • the sample is obtained prior to treatment with the LAG-3 antibody. In some embodiments, the sample is obtained after the cancer has metastasized. In some embodiments, the sample is a formalin-fixed, paraffin-coated (FFPE) sample. In some embodiments, the sample is a biopsy (eg, a core biopsy), a surgical specimen (eg, a specimen from a surgical resection), or a fine needle aspirate.
  • FFPE formalin-fixed, paraffin-coated
  • LAG-3 is detected prior to treatment, eg, prior to initiation of treatment or prior to a treatment following a treatment interval.
  • a method of treating a tumor or infection comprising: testing a subject (eg, a sample) (eg, a subject sample comprising cancer cells) for the presence of LAG-3, The LAG-3 value is thus determined, the LAG-3 value is compared to a control value (eg, the value of LAG-3 in a sample from a healthy individual), and if the LAG-3 value is greater than the control value, a therapeutically effective amount is administered to the subject of LAG-3 antibodies (eg, LAG-3 antibodies described herein), optionally in combination with one or more other therapies, thereby treating tumors or infections.
  • a subject eg, a sample
  • a subject sample eg, a subject sample comprising cancer cells
  • Example 1 Preparation and screening of anti-human LAG-3 antibody hybridoma cells
  • the human LAG-3 extracellular region (NCBI accession number: NP_002277.4, 1aa-450aa) was fused to mouse Fc to obtain hLAG-3-mFc fusion protein, which was used to immunize Balb/c mice to stimulate the immune response.
  • the human LAG-3 extracellular region (NCBI accession number: NP_002277.4, 1aa-450aa) was fused to human Fc to obtain hLAG-3-hFc fusion protein, and the hLAG-3-hFc fusion protein was used to coat a 96-well microtiter plate , the anti-hLAG-3 antibody titer in mouse serum was detected by enzyme-linked immunosorbent assay (ELISA) after immunizing Balb/c mice with hLAG-3-mFc fusion protein.
  • ELISA enzyme-linked immunosorbent assay
  • mice When Balb/c mice had a high titer of anti-hLAG-3 antibody and produced the desired immune response, the mice were immunized with hLAG-3-mFc fusion protein, and the mice were aseptically removed 3 days later.
  • rat spleen The spleen cells of Balb/c mice were collected to prepare a cell suspension and fused with SP2/0 myeloma cells. After the fused cells were resuspended in HAT medium, they were dispensed into 96-well cell culture plates. Incubate in a 37°C, 5% CO 2 incubator to form hybridoma cell lines.
  • PC positive control
  • NC negative control
  • Murine anti-human LAG-3 antibody clones 7C5, 4C8, 7F1, 7F10, 3A10 and 10B4 were selected as exemplary candidate clones for sequence determination.
  • amino acid sequence is shown in SEQ ID NO: 8; the amino acid sequence of the 3A10 mouse antibody heavy chain variable region amino acid sequence is shown in SEQ ID NO: 9, and the light chain variable region amino acid sequence is shown in SEQ ID NO: 10; 10B4 mouse antibody heavy chain variable region amino acid sequence See SEQ ID NO: 11, and the light chain variable region amino acid sequence is shown in SEQ ID NO: 12.
  • the 7C5, 4C8, 7F1, 7F10, 3A10 and 10B4 murine antibody light chain variable region and heavy chain variable region nucleotide sequences obtained in Example 2 were cloned into a heavy chain containing human-kappa light chain constant region and human IgG4, respectively.
  • Human-mouse chimeric light chains (ch7C5L, ch4C8L, ch7F1L, ch7F10L, ch3A10L and ch10B4L) and human-mouse chimeric light chains (ch7C5L, ch4C8L, ch7F1L, ch7F10L, ch3A10L and ch10B4L) and Chimeric heavy chain (ch7C5H, ch4C8H, ch7F1H, ch7F10H, ch3A10H and ch10B4H) expression plasmids were transformed into HEK293 cells (ATCC) for recombinant expression.
  • ATCC HEK293 cells
  • control antibody BMS-986016 light and heavy chain sequences were fully synthesized, cloned into a eukaryotic transient expression vector, and recombinantly expressed in HEK293 cells. 5-6 days after the cells were transfected, the culture supernatant was taken, and the expression supernatant was purified by ProteinA affinity chromatography to obtain BMS-986016 recombinant protein.
  • the amino acid sequence of the control antibody BMS-986016 is derived from WHO Drug Information (Vol.32, No.2, 2018), the amino acid sequence of the heavy chain is shown in Sequence 13, and the amino acid sequence of the light chain is shown in Sequence 14.
  • SEQ ID NO: 13 Control antibody BMS-986016 heavy chain amino acid sequence
  • the affinity of the chimeric antibody in Example 3 was determined by the method of capturing the Fc segment of the antibody with the capture antibody (AHC) biological probe against the Fc segment of the human antibody.
  • the specific operations are as follows.
  • the ch7C5, ch4C8, ch7F1, ch7F10, ch3A10, and ch10B4 chimeric antibodies were diluted with PBS buffer to 4 ⁇ g/ml, respectively, and flowed over the surface of AHC probe (Cat: 18-0015, PALL) for 120 s.
  • the hLAG-3-mFc fusion protein (60nM) obtained by fusion of human LAG-3 extracellular domain (NCBI accession number: NP_002277.4, 1aa-450aa) to mouse Fc was used as mobile phase, the binding time was 300s, and the dissociation time was 300s. for 300s.
  • the response value of the blank control was deducted, and the 1:1 Langmuir binding mode was fitted with the software to calculate the kinetic constant of antigen-antibody binding.
  • Example 5 FACS detection of binding of anti-human LAG-3 chimeric antibody to LAG-3 on HEK293 cell surface
  • HEK293 cell line transiently expressing human LAG-3 The transient expression plasmid encoding full-length human LAG-3 (NCBI accession number: NP_002277.4) was transferred into HEK293 cells by liposome method, and transfected After 48 hours, the obtained cells (hereinafter also referred to as 293/rhLAG-3 cells) were used for FACS detection.
  • the 293/rhLAG-3 cell suspension was incubated with different concentrations of ch7C5, ch4C8, ch7F1, ch7F10, ch3A10, and ch10B4 chimeric antibodies for 30 min at room temperature. After washing the cells three times with PBS, 1:200 diluted goat anti-human was added. IgG-FITC (Cat: F9512, Sigma) and incubated for 30 min.
  • the cells were washed with PBS for 3 times by flow cytometry, and the mean fluorescence intensity (MFI) of the cells was detected to detect the binding ability of the chimeric antibody to LAG-3 on the cell surface.
  • MFI mean fluorescence intensity
  • ch7C5, ch4C8, ch7F1, ch7F10, ch3A10, ch10B4 can all bind to LAG-3 on the surface of 293 cells, and the specific binding map is shown in Figure 1.
  • the ch7C5, ch4C8, ch7F1, ch7F10, ch3A10, ch10B4 chimeric antibodies showed specific binding to human LAG-3 on the surface of HEK293 cells compared to the isotype control.
  • Example 6 FACS detection of blocking activity of anti-human LAG-3 chimeric antibody on the binding of HLA to LAG-3 on the surface of 293 cells
  • Construction of 293 cell line transiently expressing human HLA encoding full-length human HLA-A (Cat: HG13263-UT, Beijing Yiqiao Shenzhou Technology Co., Ltd.) and HLA-B (Cat: HG16629-UT, Beijing Yiqiao Shenzhou Co., Ltd.) Technology Co., Ltd.) was co-transfected into HEK293 cells by liposome method, and 48 hours after transfection, the obtained cells (hereinafter also referred to as 293/rhHLA cells) were used for FACS detection.
  • ch7C5, ch4C8, ch7F1, ch7F10, ch3A10, ch10B4 chimeric antibodies and 2ug/ml hLAG-3-mFc fusion protein were incubated at room temperature for 60min, then added to 293/rhHLA cell suspension and incubated at 4°C For 60 min, after washing the cells three times with PBS, 1:200 diluted goat anti-mouse IgG-FITC (Cat: F9006, Sigma) was added and incubated for 30 min.
  • MFI mean fluorescence intensity
  • Example 7 Humanization and recombinant expression of anti-human LAG-3 monoclonal antibody
  • the sequence of the heavy chain of the murine antibody was comprehensively analyzed to determine the complementary determinant (CDR) region of the antibody binding to the antigen and the framework region (framework) supporting the conserved three-dimensional conformation of the antibody.
  • CDR complementary determinant
  • the most similar human antibody template VH1 (1-46) was selected as the basic template, combined with the full sequence blast results, CDR transplantation was performed, and according to the CDR3 sequence, JH4 (WGQGTLVTVSS) was selected as the J region sequence.
  • CDR transplantation was carried out to realize the humanization of 7F10 heavy chain variable region (VH) in the framework region.
  • VK I (O12) and VKIII (L25) were selected as the basic templates, combined with the full sequence blast results, and CDR transplantation was carried out.
  • JK2 (FGQGTKLEIK) was selected as the JK region sequence to realize the light chain. Humanization of framework regions.
  • the amino acid sequence of the humanized heavy chain variable region hz7F10_VH1 of 7F10 antibody CDR Grafted is shown in SEQ ID NO: 15; the amino acid sequence of the humanized light chain variable region hz7F10_VL1 amino acid sequence is shown in SEQ ID NO: 16, and the humanized light chain The variable region hz7F10_VL2 amino acid sequence is shown in SEQ ID NO:17.
  • SEQ ID NO: 15 Humanized antibody hz7F10 heavy chain variable region VH1 amino acid sequence
  • SEQ ID NO: 16 Humanized antibody hz7F10 light chain variable region VL1 amino acid sequence
  • SEQ ID NO: 17 Humanized antibody hz7F10 light chain variable region VL2 amino acid sequence
  • hz7F10_VH1 represents the first hz7F10 heavy chain variable region
  • hz7F10_VH2 represents the second hz7F10 heavy chain variable region
  • hz7F10_VH7 represents the seventh hz7F10 heavy chain variable region
  • hz7F10_VL Humanized hz7F10 light chain variable regions are named herein as follows: hz7F10_VL followed by a numerical identification number, eg, 1, 2, 3, 4, 5, 6, 7. Therefore, according to this nomenclature, for example, hz7F10_VL1 represents the first hz7F10 light chain variable region, hz7F10_VL2 represents the second hz7F10 light chain variable region, and hz7F10_VL7 represents the seventh hz7F10 light chain variable region;
  • Q1E in the table represents that the amino acid Q at position 1 of the "CDR-grafted" sequence SEQ ID NO: 15 in the corresponding column is mutated to E;
  • Y36F represents the mutation of amino acid Y at position 36 of the "CDR-grafted" sequence SEQ ID NO: 16 of the corresponding column to F;
  • N53T represents the mutation of amino acid N at position 53 of the "CDR-grafted" sequence SEQ ID NO: 17 of the corresponding column to T.
  • SEQ ID NO: 18 Humanized antibody hz7F10 heavy chain variable region VH2 amino acid sequence
  • SEQ ID NO: 19 Humanized antibody hz7F10 heavy chain variable region VH3 amino acid sequence
  • SEQ ID NO:20 Humanized antibody hz7F10 heavy chain variable region VH4 amino acid sequence
  • SEQ ID NO: 21 Humanized antibody hz7F10 heavy chain variable region VH5 amino acid sequence
  • SEQ ID NO: 22 Humanized antibody hz7F10 heavy chain variable region VH6 amino acid sequence
  • SEQ ID NO: 23 Humanized antibody hz7F10 heavy chain variable region VH7 amino acid sequence
  • SEQ ID NO: 24 Humanized antibody hz7F10 light chain variable region VL3 amino acid sequence
  • SEQ ID NO: 25 Humanized antibody hz7F10 light chain variable region VL4 amino acid sequence
  • SEQ ID NO: 26 Humanized antibody hz7F10 light chain variable region VL5 amino acid sequence
  • SEQ ID NO: 27 Humanized antibody hz7F10 light chain variable region VL6 amino acid sequence
  • SEQ ID NO: 28 Humanized antibody hz7F10 light chain variable region VL7 amino acid sequence
  • the humanized designed hz7F10 antibody light and heavy chain variable region sequences (hz7F10_VL1, hz7F10_VL2, hz7F10_VH1) were fully synthesized, and the humanized heavy chain variable regions were cloned into the eukaryotic transient expression vector pCDNA3.1 (catalog number: V79520 , Invitrogen) the upstream of the heavy chain constant region encoding gene of human IgG4, the heavy chain constant region amino acid sequence is shown in sequence 29; the humanized light chain variable region is cloned into the eukaryotic transient expression vector encoding of the human light chain CK Upstream of the gene, the amino acid sequence of the light chain constant region is shown in sequence 30, and the light and heavy chain expression vectors of the humanized hz7F10 antibody are constructed.
  • SEQ ID NO: 29 Heavy chain constant region amino acid sequence
  • SEQ ID NO:30 Light chain constant region amino acid sequence
  • the cells were transfected, they were cultured with FreeStyle293 medium (catalog number: 12338-018, Gibco), the culture supernatant was taken, and the expression supernatant was purified by ProteinA affinity chromatography to obtain a humanized antibody.
  • FreeStyle293 medium catalog number: 12338-018, Gibco
  • the antibody affinity was determined by using the capture antibody (AHC) biological probe against the Fc segment of the human antibody to capture the Fc segment of the antibody.
  • AHC capture antibody
  • hz7F10 antibody and chimeric antibody ch7F10 were diluted with PBS buffer to 4ug/mL, and flowed through the surface of AHC probe (Cat:18-0015, PALL) for 300S.
  • hLAG-3-mFc recombinant protein was used as mobile phase at a concentration of 60 nM.
  • the binding time was 300s and the dissociation time was 300s.
  • the software was used to fit the 1:1 Langmuir binding mode to calculate the kinetic constant of antigen-antibody binding.
  • Example 8 Species specificity study of ELISA detection of anti-LAG-3 humanized antibody binding to LAG-3
  • Human LAG-3-mFc recombinant protein cynomolgus monkey LAG-3 recombinant protein (Cat: 90841-C08H, Beijing Yiqiao Shenzhou Technology Co., Ltd.), mouse LAG-3 recombinant protein (Cat: 53069-M08H, Beijing Yiqiao Shenzhou Technology Co., Ltd.), coated overnight at 4°C, and the coating concentration was 1 ⁇ g/mL; after washing the plate three times with PBS, add 5% BSA PBS, block at 37°C for 60 min, and wash the plate three times with PBST; add different dilution times hz7F10-23 (initial concentration of 10 ⁇ g/mL, 3-fold gradient dilution for 12 concentrations), incubated at 37°C for 60 min, washed 4 times with PBST; added 1:5000 diluted HRP-anti-human Fc (Cat: 109- 035-098, Jackson Immuno Research), incubate at 37°C for
  • Antibody name EC50 for binding to human LAG-3 EC50 for binding to cynomolgus monkey LAG-3 hz7F10-23 0.034nM 0.20nM
  • the antibody affinity was determined by using the capture antibody (AHC) biological probe against the Fc segment of the human antibody to capture the Fc segment of the antibody.
  • AHC capture antibody
  • Antibodies (hz7F10-23 and control antibody BMS-986016) were diluted to 4 ug/mL with PBS buffer and flowed over the surface of AHC probe (Cat: 18-0015, PALL) for 120 s.
  • Human LAG-3-mFc recombinant protein was used as mobile phase.
  • the binding time was 300s and the dissociation time was 300s.
  • the response value of the blank control was deducted, and the 1:1 Langmuir binding mode was fitted with the software to calculate the kinetic constant of antigen-antibody binding.
  • the binding reaction curves of antibody hz7F10-23 and control antibody BMS-986016 to human LAG-3 recombinant protein are shown in Figure 6 and Figure 7, respectively. Curves were fitted and binding affinities were calculated, the hz7F10-23 affinity (KD) was 4.17E -11M and the BMS-986016 affinity (KD) was 1.61E -10M. The specific kinetic parameters are shown in Table 9 below. The results showed that hz7F10-23 had a high affinity for human LAG-3, which was better than that of the control antibody BMS-986016.
  • Example 10 FACS detection of binding of anti-human LAG-3 humanized antibody to LAG-3 on the surface of 293 cells
  • the 293/rhLAG-3 cell suspension was incubated with different concentrations of humanized antibody hz7F10-23 and control antibody BMS-986016 for 30 min at room temperature. After washing the cells three times with PBS, 1:200 diluted goat anti-human IgG was added. -FITC (Cat: F9512, Sigma) and incubated for 30 min. After washing the cells three times with PBS, the cells were subjected to flow cytometry to detect the mean fluorescence intensity (MFI) of the cells to detect the binding ability of the humanized antibody to LAG-3 on the cell surface.
  • MFI mean fluorescence intensity
  • the antibody hz7F10-23 can bind to LAG-3 on the surface of 293 cells, and it can be seen from Figure 8 that the binding ability of the antibody hz7F10-23 to the cell surface LAG-3 is better than that of the control antibody BMS-986016.
  • the half effective binding concentration EC50 values of the antibody hz7F10-23 and the control antibody BMS-986016 were 1.6nM and 1.5nM, respectively, and the binding abilities of the two were equivalent.
  • Example 11 ELISA detection of the blocking activity of anti-LAG-3 humanized antibodies to the binding of LAG-3 to FGL-1
  • Human FGL-1 recombinant protein (Cat: CW55, Inshore Bio) was coated on a 96-well plate overnight at 4°C with a coating concentration of 0.5 ⁇ g/mL; after washing the plate three times with PBS, 5% BSA PBS was added, and the plate was blocked at 37°C for 60 min , PBST washed 3 times; different concentrations of hz7F10-23 and control antibody BMS-986016 and 0.02ug/ml LAG-3-mFc (NCBI accession number: NP_002277.4, 1aa-450aa) were pre-incubated at 37°C for 30min Then, add it to the coated wells, incubate at 37°C for 60min, wash the plate 4 times with PBST; add 1:5000 diluted HRP anti-mouse IgG (Cat: 115-035-071, Jackson Immuno Research), incubate at 37°C for 45min, The plate was washed 4 times with PBST;
  • both the humanized antibody hz7F10-23 and the control antibody can specifically block the binding of human LAG-3 to FGL-1, and their corresponding half effective inhibitory concentration IC50 values are 0.038nM, 0.038nM, respectively.
  • the blocking activity is comparable.
  • Example 12 FACS detection of the blocking activity of anti-human LAG-3 humanized antibody on the binding of HLA to LAG-3 on the surface of 293 cells
  • the antibody hz7F10-23 can block the binding of cell surface HLA and recombinant LAG-3 protein, and the blocking ability is better than that of the control antibody.
  • the half effective inhibition concentration IC50 values of hz7F10-23 and control antibody BMS-986016 are respectively were 4.8nM and 9.9nM.
  • Example 13 Pharmacodynamic evaluation of anti-LAG-3 antibody in B6-huPD1huLAG3 humanized mouse subcutaneous xenograft model
  • mice B6-huPD1huLAG3 (Jicui Yaokang, catalog number: T004621) were taken and subcutaneously inoculated with 3 ⁇ 10 6 MC38 mouse colon adenocarcinoma cells (ATCC) , when the tumor grows to about 100mm 3 , random grouping, 6 animals/group, grouping, dosage and frequency are shown in Table 10. Each group is intraperitoneally administered twice a week for a total of 6 times, and the tumor is measured at the same time.
  • mice Volume and body weight of mice, when the body weight of mice decreased by more than 15%, or when the tumor volume of a single animal exceeded 3000mm 3 or the average tumor volume of a group of animals exceeded 2000mm 3 , the experiments on related mice were stopped, and the mice were euthanized.
  • Dosing frequency 1 isotype control 10mg/kg Biw ⁇ 6 2 hz7F10-23 10mg/kg Biw ⁇ 6 3 BMS-986016 10mg/kg Biw ⁇ 6

Abstract

L'invention concerne des anticorps et des fragments d'anticorps se liant spécifiquement à LAG-3, et des compositions pharmaceutiques contenant ces anticorps ou ces fragments d'anticorps. L'invention concerne également un acide nucléique codant pour lesdits anticorps, une cellule hôte comprenant cet acide nucléique, et un procédé de préparation desdits anticorps. L'invention concerne en outre des utilisations thérapeutiques et diagnostiques des anticorps se liant à LAG-3.
PCT/CN2022/075525 2021-02-08 2022-02-08 Anticorps se liant à lag-3 et leur utilisation WO2022166987A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110171586 2021-02-08
CN202110171586.8 2021-02-08

Publications (1)

Publication Number Publication Date
WO2022166987A1 true WO2022166987A1 (fr) 2022-08-11

Family

ID=82742012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/075525 WO2022166987A1 (fr) 2021-02-08 2022-02-08 Anticorps se liant à lag-3 et leur utilisation

Country Status (2)

Country Link
CN (1) CN114907478A (fr)
WO (1) WO2022166987A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180127496A1 (en) * 2015-02-03 2018-05-10 Anaptysbio, Inc. Antibodies directed against lymphocyte activation gene 3 (lag-3)
CN108472349A (zh) * 2016-06-23 2018-08-31 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
WO2019141092A1 (fr) * 2018-01-18 2019-07-25 四川科伦博泰生物医药股份有限公司 Anticorps anti-lag-3 et son utilisation
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用
CN111050792A (zh) * 2017-08-30 2020-04-21 凡恩世制药公司 抗lag-3抗体及其用途
CN112074541A (zh) * 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180127496A1 (en) * 2015-02-03 2018-05-10 Anaptysbio, Inc. Antibodies directed against lymphocyte activation gene 3 (lag-3)
CN108472349A (zh) * 2016-06-23 2018-08-31 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
CN111050792A (zh) * 2017-08-30 2020-04-21 凡恩世制药公司 抗lag-3抗体及其用途
WO2019141092A1 (fr) * 2018-01-18 2019-07-25 四川科伦博泰生物医药股份有限公司 Anticorps anti-lag-3 et son utilisation
CN112074541A (zh) * 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN XIUXIU;YU XIAOJIE;LIU JIANFEI;WU CHENGLIN;QIN KEWEI;ZHOU LIJUN: "Preparation of Anti-lymphocyte Activation Gene 3 (LAG-3) Fully Human Antibodies", CHINESE JOURNAL OF CELLULAR AND MOLECULAR IMMUNOLOGY, vol. 36, no. 5, 18 May 2020 (2020-05-18), pages 451 - 456, XP055956448, ISSN: 1007-8738, DOI: 10.13423/j.cnki.cjcmi.009022 *
YU XIAOJIE, HUANG XIAO, CHEN XIUXIU, LIU JIANFEI, WU CHENGLIN, PU QIAN, WANG YUXIAO, KANG XIAOQIANG, ZHOU LIJUN: "Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy", MABS, vol. 11, no. 6, 18 August 2019 (2019-08-18), US , pages 1139 - 1148, XP055825981, ISSN: 1942-0862, DOI: 10.1080/19420862.2019.1629239 *

Also Published As

Publication number Publication date
CN114907478A (zh) 2022-08-16

Similar Documents

Publication Publication Date Title
CA3092456C (fr) Anticorps anti-tigit et utilisation connexe
WO2017071625A1 (fr) Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci
JP2020504627A (ja) 抗ｐｄ−１抗体及びその使用
CN110431231B (zh) 抗-cd3抗体和包含所述抗体的分子
CA3043691C (fr) Anticorps se liant specifiquement a cd66c et utilisation associee
WO2020151762A1 (fr) Nouvelle molécule d'anticorps bispécifique et anticorps bispécifique combinant simultanément pd-l1 et lag-3
CN113906053B (zh) 抗cea抗体及其应用
WO2019242619A1 (fr) Anticorps anti-lag-3 complètement humanisé et son application
US20220153863A1 (en) Prame binding molecules and uses thereof
JP2023540526A (ja) ネクチン－４抗体およびそれの使用
WO2023151693A1 (fr) Composition pharmaceutique comprenant un anticorps anti-tigit et un anticorps bispécifique anti-pd-1-anti-vegfa, et utilisation
WO2019022187A1 (fr) Anticorps anti cd147
JP2022518062A (ja) 抗ｃｄ７９ｂ抗体、その抗原結合フラグメントおよびそれらの医薬用途
EP4286410A1 (fr) Anticorps à un seul domaine contre cd16a et son utilisation
WO2022166987A1 (fr) Anticorps se liant à lag-3 et leur utilisation
KR20230009459A (ko) 인간 ceacam1/3/5에 특이적으로 결합하는 신규 항체 및 그의 용도
WO2020186158A2 (fr) Molécules de liaison de prame et leurs utilisations
CN114761042A (zh) Il-38特异性抗体
WO2023001303A1 (fr) Composition pharmaceutique et son utilisation
JP7478222B2 (ja) 抗ｃｄ３抗体及び該抗体を含む分子
WO2023103962A1 (fr) Molécule de liaison à tnfr2 et son utilisation
WO2022247905A1 (fr) Anticorps anti-cd40 et son utilisation
WO2023173393A1 (fr) Anticorps se liant à b7-h3 et son utilisation
RU2790326C2 (ru) Анти-сd3-антитело и молекула, содержащая это антитело
EP4337698A1 (fr) Agents de liaison à l'intégrine alpha 5 bêta 1 et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22749266

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22749266

Country of ref document: EP

Kind code of ref document: A1